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Summary
The function of the thymus is to provide the physiological microenvironment for the 
development of T lymphocytes. In this function, thymic epithelial cells play a critical role for 
the successful establishment and maintenance of the immune system’s capacity to distinguish 
between self and non-self. The cellular and architectural organizations of the thymus provide 
functionally distinct regions that control the separate and discrete maturational steps in 
the ordered differentiation from precursor cells to phenotypically mature and functionally 
competent T cells. The appropriate choice of the T cell antigen receptor (TcR) repertoire is 
the consequence of interactions with MHC classes I and II molecules on thymic epithelial 
cells (and other stromal cell types) underscoring the importance of thymic epithelial cells 
for thymocyte differentiation and selection. However, thymic epithelial cell homeostasis is 
severely disrupted after conditioning with radio-chemotherapy and allogeneic recognition by 
donor T cells in the context of allogeneic hematopoietic stem cell transplantation (HSCT). HSCT 
is the therapy of choice for a number of malignant and non -malignant diseases. The success 
of allogeneic HSCT depends on the efficiency by which the host’s immune system is restored. 
The thymus is one of the target organs of donor derived T cells and is severely damaged 
after HSCT. For this reason, the T-cell lineage is not re-generated as rapidly and efficiently 
as most other hematological lineages, which results in a protracted immune deficiency in the 
post-transplant period. Recent studies aimed at a better understanding of the regenerative 
mechanisms demonstrated that the donor-derived peripheral T-cell pool is restored through 
two independent pathways: (i) expansion of adoptively transferred mature T-cells, and (ii) 
intrathymic de novo generation of T-cells from donor-derived precursor cells. While transfer 
of mature T-cells during allogeneic HSCT may provide a short-term restoration of immune 
functions, but is limited by the complication of Graft versus Host Diseases (GVHD), the long-
lasting and complete reconstitution of the peripheral T cell pool depends ultimately on new T 
cell generation.
Keratinocyte growth factor  (KGF; a.k.a. Fibroblast Growth Factor 7) was described as a key 
effector molecule for the protection/restoration of epithelial cells following radio- chemo-
therapeutic conditioning; although the precise mechanism of action remain unknown. The 
presented thesis details the biological effects of KGF on the thymic microenvironment and its 
functions during postnatal homeostasis of the thymus and during T cell mediated damage in 
the course of GVHD.
To investigate the molecular and cellular basis for the effect of KGF on function and 
architecture of thymic epithelial cells, different experimental systems were investigated. The in 
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vitro proliferation capacity of different thymic epithelial cell lines in response to KGF exposure 
was tested and fetal thymic organ cultures (FTOC) were employed to analyze the effect of 
KGF in the complex ex vivo conditions. Additionally, thymic architecture and function were 
also investigated following the in vivo exposure to KGF. Under these conditions KGF induced 
the proliferation of thymic epithelial cells. Gene expression analysis of thymic epithelial 
cells treated ex vivo or in vivo with KGF revealed the upregulation of specific transcripts for 
Wnt and Bmp family members and IL-7, i.e. molecules known to regulate thymopoiesis. In 
consequence, KGF also stimulated an increase in thymic T lymphopoiesis resulting in an 
increase in size, weight and cellularity. Most importantly, KGF did not alter the architectural 
organization and the composition of the thymic epithelial subpopulation, thus allowing for 
a regular expansion and selection of thymocytes. These characteristics identified KGF as an 
ideal candidate for the preservation/restoration of thymic epithelial cell injury in the presence 
of acute GVHD. Indeed, when given to recipients of allogeneic T cells in a non-irradiated 
murine P->F1 transplantation model, KGF preserved normal thymic size, cellularity, epithelial 
cell architecture and thymocyte maturation. This normal function and phenotypic appearance 
of the thymus correlated with a decreased infiltration by donor-derived T cells. In addition, 
the typical GVHD-induced impairment in cell cycle progression of pro- and pre-T cells was 
also prevented by KGF. Moreover, the treatment with KGF decreased the number and in situ 
activation of infiltrating allogeneic T cells and drives the disease from an acute into a chronic 
course.
Taken together, these findings have detailed the role of KGF for thymic epithelial cell biology 
under physiological growth conditions, tissue maintenance, epithelial cell repair and protection 
in the presence of thymic GVHD.
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Introduction
The thymus is the primary site for the development of T cells of the TcRαβ lineage (reviewed 
in (1, 2)), whereby intrathymic lymphopoiesis is regulated by an active cross-talk between 
lymphoid cells and different stromal cells. Hematopoietic stem cells originating from bone 
marrow home to the thymus via the blood circulation, undergo a process of expansion, 
maturation and TcR repertoire selection, and finally emigrate to the periphery as mature T 
cells.
Thymus development
Structure and cellular composition of the thymus
The thymus lies in the upper mediastinum above the heart and is a pyramid-shaped organ 
formed of two structurally identical lobes that meet in the midline (Figure I). A connective 
tissue capsule surround each lobe, which is 
comprised of numerous lobules, formed by 
invagination of connective tissue derived from 
the capsule. Analysis of the thymic structure at 
the histological level allows the distinction of 
three separate areas: The thin subcapsular region, 
the lymphocyte-rich cortex and the epithelial 
cell-dense medulla (Figure II). In conventional 
light microscopy, the cortex is separated from the 
medulla by a clearly visible cortico-medullary 
junction (CMJ). Strands of connective tissue 
extend at irregular intervals from the surface of 
the thymus into the organ proper and, therefore, 
form septa that carry nerve bundles, blood vessels and the efferent lymphatics that drain 
the connective tissues of both septa and capsules. Thymocytes develop in physical contact 
with several types of stromal cells which, combined, create distinct microenvironments 
composed of epithelial cells and non-epithelial cells such as fibroblasts, macrophages, and 
dendritic cells. The autochthonous epithelial cells constitute the most abundant population 
of stromal cells and their function is clearly distinct from that of the bone marrow-derived 
hematopoietic stromal cells. Combined, the epithelial cells form an integrated cellular 
network that provides distinct developmental niches for cells of the T lymphoid lineage. 
Thyroid
Thymus
Right lung
Left lung
Figure I The thymus is positioned above the 
heart. Adapted from www.cancerhelp.org.uk
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Using phenotypic characteristics such as cell 
surface antigen expression and morphology in 
electron microscopy, the compartment of thymic 
epithelial cells can be distinguished in cortical 
and medullary epithelial cells, respectively and 
several subpopulations therein (see below). The 
bone marrow-derived dendritic cells are located 
in the medulla where they primarily are detected 
in the vicinity of the CMJ. In contrast thymic 
macrophages can be detected in both cortex 
and medulla (2). B cells are also present in the 
thymus (3, 4). Thymic B cells were thought to be 
involved in the maintenance of T cell tolerance 
to self antigens, including those expressed by B cells (5, 6). However, it appeared that B cells 
are not the only cell type responsible for tolerance induction. Recently, several reports have 
described B lymphopoiesis in the thymus (7). In the thymus of young normal mice, CD117+, 
B220low pro- and pre-B cells are present but disappear with age. B220low, CD5+, B-1 B cells are 
present in the thymus of older animals (8). 
Epithelial cells, which are the major component of the thymic stromal cells, generate the 
three-dimensionally (3-D) organized meshwork architecture peculiar to the thymus. In 
contrast, in other epithelial organs, e.g. the visceral organs and skin, epithelial cells are placed 
on the basement membranes and make close contact with adjacent cells forming sheets. 
The meshwork architecture of the thymus is formed through a marked change of epithelial 
organization during organogenesis of the thymus anlage. Epithelial cells of the mouse thymus 
anlage originate in the third pharyngeal pouch endoderm and the third pharyngeal cleft 
ectoderm. Protrusion of both epithelial layers into the pharyngeal arch mesenchymal region 
on E9–11 results in formation of the thymus anlage (9). Epithelial cells of the thymus anlage 
develop through interactions of thymic mesenchymal cells (10-13) and developing thymocytes 
(14-18); finally generate a 3-D organized meshwork architecture (19, 20).
Organogenesis and thymic epithelial cell development
The process of organogenesis consists of several independent stages of maturation that 
combined assure the correct composition, architectural organization, and function of an 
organ. In the case of the thymus, the individual maturational steps include the events of 
positioning, induction, outgrowth, patterning, and differentiation. The end product of this 
complex process is a fully developed primary lymphoid organ competent to generate mature 
M
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SCA
CMJ
Figure II Thymus section from a healthy mouse. 
Hematoxilin and Fast Red stain. M: medulla, C: 
cortex, CMJ: cortico-medullary junction, SCA: 
sub capsular area, S: septum. (40x)
S
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thymocytes. Thymic organogenesis can be distinguished into three different phases: the early 
organogenesis corresponds to events that occur between E9.5 – E11 of mouse development, the 
phase of late organogenesis occurs between E11.5 and E15, while maturational changes to the 
thymus organ during late fetal development take place between E15.5 and birth. While each of 
these phases appears to be regulated by their own set of genetic controls, the formation of the 
early thymic primordium is furthermore dependent on a coordinated interaction of all three 
embryonic germ layers, i.e. (i) the endoderm from the epithelial lining of the ventral aspects 
of the third pharyngeal pouch; (ii) the neuroectoderm-derived neural crest mesenchyme; 
and (iii) the mesoderm-derived hematopoietic and endothelial cells (reviewed in (21)).  The 
commitment to a thymic epithelial cell fate is exclusively restricted to endodermal endothelium 
of the ventral aspect of the third pharyngeal pouch by a genetic program yet to be completely 
defined. While it has been thought that epithelial cells of ectodermal origin (i.e. branchial 
cleft) would also contribute to the epithelial primordium of the thymus, recent experiments 
using cell tracking and microsurgery methods have provided ample evidence that ectodermal 
epithelium does not play a role in the formation of the thymus. Epithelial cells destined to a 
thymic fate form a bilateral epithelial bud, which eventually detaches from the lining of the 
third pharyngeal pouch. These primordia migrate by E12.5 to a midline positioned on top of 
the heart. In late fetal development, the thymus, which by now harbors lymphocytes at stages 
of early and intermediate cell development, begins to display a distinction into a cortical and 
into a medullary compartment (reviewed in (22)). These areas have separate functions and 
hold different populations of thymic epithelial cells (Figure III). Recently, a common precursor 
population for all 
thymic epithelial cells 
has been isolated using 
a cell surface phenotype 
characterized by the 
monoclonal antibody 
MTS24 (23-25) 
(reviewed in (26)). 
This antibody stains 
epithelium of the third 
pharyngeal pouch 
as early as E10.5 and 
identifies all epithelial cells that form the thymic primordium at E11.5. The MTS24 antibody 
recognizes the protein backbone of a glycoprotein yet to be defined at the genetic level. The 
functional capacity of MTS24+ thymic epithelial cells was demonstrated in cell transfer studies 
where MTS24+ cells from E15.5 embryos were isolated by flow cytometry and engrafted 
Neural crest
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Epithelium from 3rd pharin-
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Figure III Thymic epi-
thelial cell development. 
Several studies have high-
lighted a number of genes 
which seem to directly in-
fluence the maturational 
programme of thymic epi-
thelium. In addition stud-
ies on genetic mutations 
in immature thymocytes 
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derson et al., Nature reviews 
Immunology, 2001.
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under the kidney capsule of syngeneic recipients. Here, these precursor cells gave rise to a 
structurally complete and functionally competent thymus supporting regular thymopoiesis. 
While positivity for the MTS24-recognized epitope identifies epithelium giving rise to the 
thymus, positive staining with this antibody occurs also in other anatomical locations; this 
epitope is thus not exclusive for epithelial precursors involved in thymic organogenesis. 
The presence of MTS24+ thymic epithelial cells within the developing thymus is drastically 
reduced by E15.5 but can still be detected in thymic tissue of adult mice. Here, MTS24+ cells 
are located in the outer aspects of the medulla closed to the CMJ where they occasionally 
form small clusters. To further characterize the phenotype of MTS24+ cells, sections of thymic 
tissue were analyzed at E11.5 and E12.5 for the expression of cytokeratins (CK). It appears 
from these studies that both CK5 and CK8/18 are co-expressed by a majority of MTS24+ 
thymic epithelial cells (24). This result further supports the notion that MTS24+ cells operate 
as a common precursor cell to all thymic epithelial cells as the expression of CK8/18 serves 
as a typical marker for cortical thymic epithelial cells while the expression of CK5 is typically 
localized to medullary epithelial cells. Thus, the co-expression of specific cellular markers 
early in thymic ontogeny and their segregation into distinct cellular compartments define 
distinct subpopulation of epithelial cells and at later developmental stages has been taken as 
indication for a common precursor to both cortical and medullary epithelial cells ((23, 24, 27, 
28) and reviewed in (26)). The subdivision of thymic epithelial cells into cells with a cortical 
and medullary phenotype, respectively, is already apparent by E15.5. Using intracytoplasmic 
markers such as cytokeratins, reactivity to the monoclonal antibody MTS10 and binding of the 
lectin UEA-1 has allowed a further separation of epithelial cells into cortical and medullary 
subpopulations (28). For example, the major cortical subset of thymic epithelial cells is defined 
by the presence of CK8/18 but the lack of CK5 and CK14 expression. In contrast, the minor 
subpopulation of cortical epithelial cells is defined by a CK8+CK18+CK5+CK14- phenotype and 
these cells are preferentially localized to the CMJ. Cells with a stellate morphology that express 
CK5, CK14, and MTS10 but fail to stain for CK8/18 characterize the most abundant medullary 
subpopulation of epithelial cells. In contrast, the minor subpopulation of medullary epithelial 
cells has a CK8+CK18+CK5-CK14- phenotype and stains with UEA-1 lectin. Displaying a 
globular morphology, these cells are usually situated close to the CMJ (28) and are thought to 
play a role in negative thymic repertoire selection.
The maturation of thymic epithelial cells is, at least in part, controlled by molecular cues 
provided in a paracrine fashion by mesenchymal cells early in development and by developing 
thymocytes later in organogenesis. The importance of this mesenchymal-epithelial interaction 
has best been demonstrated in experiments where thymic epithelial cells were grown in the 
absence of mesenchymal cells (29). Under these conditions, thymic epithelial cells failed 
to proliferate and were incompetent to support early thymocyte development. Recently, 
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fibroblasts growth factors have been identified as a source effecting mesenchymal-epithelial 
interactions (see below). However, thymic epithelial cell differentiation beyond E12 appears to 
be independent from the presence of perithymic mesenchyme (30).        
Thymocyte development
The majority of T cells develop in the thymus following an ordered maturational process from 
an early not yet lineage determined precursor cell to a population of mature T cells. These 
cells bear an appropriately selected antigen-specific TcR repertoire and are poised to exit the 
thymus from the medulla to the periphery. Multiple, sequential steps that are phenotypically 
highlighted by a changing expression of specific cell surface antigens characterize the normal 
developmental progression during T cell maturation. The earliest immature T cells arise from 
precursors derived during fetal development from the liver and after birth from the bone 
marrow. During the very early stages of development when intrathymic vessel formation has 
not yet occurred, these precursors exit from the perithymic vasculature and enter the thymus 
anlage through the capsule. After establishment of the blood circulation, high endothelial 
venules (HEV) at the CMJ provide the site of entry for these hematopoietic precursors. The 
precise molecular mechanisms by which these cells home to the thymus are presently not 
known. The use of several cell surface markers allows to distinguish several distinct thymocyte 
subpopulations (Figure IV). Using the expression of the glycoproteins CD4 and CD8, four 
maturational subpopulations of T cells of the αβ TcR lineage can be recognized: approximately 
5 % of the cells express neither CD4 nor CD8 and are thus designated double-negative (DN) 
cells. These DN cells are the immediate precursors to thymocytes that concomitantly express 
both CD4 and CD8 (defined as double-positive (DP) cells). DP cells constitute the most 
abundant subpopulation as these cells make up for approximately 80 % of all thymocytes. 
Later in development, thymocytes express (together with a complete T cell antigen receptor, 
TcR) either only CD4 (CD4-single positive, CD4 SP cells ∼10 %) or only CD8 (CD8 SP cells, 
∼5 %) and constitute the population of mature intrathymic T cells (31). The population of TN 
thymocytes of the αβ TcR lineage can further be separated using the expression profile of two 
other cell surface markers, i.e. CD25 (32) and CD44 (33, 34). The most immature thymocytes 
within this population express only CD44 and are designated TNI. Upon further maturation, 
these cells acquire the cell surface marker CD25 and therefore progress to the TNII stage. 
Subsequently these cells lose CD44 (TNIII) and then also CD25 (TNIV). Immune-histological 
studies have nicely demonstrated that TNI and TNII cells are located in the deeper aspects 
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of the thymus and close to the CMJ, while the TNIII cells accumulate in the subcapsular 
area of the cortex. Moreover, CD25 is within the thymus not a unique marker for TN cells 
as regulatory CD4+ T cells also express CD25 at the end of their intrathymic development 
(reviewed in (35)). 
In the course of the last few years, several additional cell surface markers have been used 
to define the phenotype of the most immature thymocytes. One study (36) designates these 
cells as early thymic precursors (ETP) and characterized them as cells negative for CD4, CD8, 
CD3, CD25, CD11b, CD19b, GR1, NK1.1, TcRαβ, TcRγδ, and IL-7R (CD127) but positive for 
CD44 and c-kit (CD117). ETPs are, therefore, considered as part of the previously defined 
DNI subpopulation of thymocytes. The acquisition of CD25 (i.e. the transition to the DNII 
phenotype) is paralleled by the D-J rearrangement of the TcRβ locus. Moreover, these cells 
begin to express the surrogate α-chain of the pre-TcR, a molecule known as pTα. While only a 
subpopulation of TNI cells stain positive for CD127, all of the TNII cells express this α-chain 
of the IL-7 receptor. Once progressed to the TNIII stage of the intrathymic T cell development, 
the cells are now also competent to express the complete pre-TcR on their cell surface, 
downmodulate CD117 expression and are rendered low positive to negative for the cell surface 
marker CD127. Signaling via the pre-TcR is a critical prerequisite for the downregulation of 
CD25 expression and thus allows the progression to a TNIV phenotype, which characterizes 
Figure IV T-cell development in the adult thymus.  Thymus is organized in distinct compartment where 
thymocytes enter in contact with different stroma cell types and differentiation can be followed accord-
ing the expression of cell-surface markers. Figure adapted from Anderson et al., Nature reviews Immunol-
ogy, 2001.
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a short-lived subpopulation of immature thymocytes. Upon further maturation, developing 
thymocytes acquire within hours the cell surface expression of CD4 and CD8 independent of 
thymic epithelial stromal support (reviewed in (1, 37)). Double-positive thymocytes rearrange 
their TcRα locus and, if successful, express a functional αβTcR on their cell surface ((38, 
39)). These cells are now rendered susceptible to positive and negative thymic selection: a 
complex process that assures the correct selection of TcR specificities: cells with a potentially 
harmful (i.e. self reactive) specificity are deleted by programmed cell death (apoptosis) while 
thymocytes bearing a TcR able to recognize foreign antigens in the context of self-MHC are 
stimulated to full maturation (40). These events occur within a relatively short window of time 
as the life span of DP cells estimate to approximately 3-4 days, regardless whether these cells 
are subjected to apoptosis as a consequence of negative selection and neglect, or whether they 
have undergone positive selection. The TcR engagement at the DP stage leading to positive 
selection induces upregulation of the TcR concomitant with an eventual downmodulation of 
either CD4 or CD8 as a consequence of the MHC-restriction of the selected antigen receptor. 
Thymocytes that recognize an antigen in the context of MHC class I develop into CD8 SP 
cells while cells bearing a TcR specific for antigens presented by MHC class II attain a CD4 SP 
phenotype. The maturational transition from DP to single-positive (SP) thymocytes is gradual, 
consists of various intermediate stages, and is paralleled by the physical translocation from the 
cortex to the medulla. In detail, positively selected DP thymocytes first downmodulate both 
CD4 and CD8 before re-expression of these glycoproteins occurs. Because CD4 re-expression is 
relatively faster when compared to that of CD8, thymocytes with a CD4low CD8 low TcRintermediate 
phenotype give first rise to CD4high CD8 low TcRintermediate thymocytes (which account for 
approximately 4 % of all thymocytes). It is only at this stage of development that the maturing 
thymocytes activate a lineage-specific program that results in a selective suppression of CD4 or 
CD8 synthesis dependent on the specificity of the selected TcR. In the case of positive selection 
of thymocytes bearing a TcR restricted for MHC class II molecules, CD4high CD8low TcRintermediate 
cells stop to express CD8 and upregulate the cell surface expression of their antigen receptor 
to obtain the CD4high CD8- TcRhigh phenotype. In contrast, thymocytes which have successfully 
engaged the complex of antigen MHC class I, maintain their CD8 re-expression while turning 
off CD4 synthesis, thus giving rise via an intermediate stage characterized by a CD4low CD8low 
TcRhigh phenotype to mature CD8high TcRhigh thymocytes. Mature SP thymocytes reside in the 
medulla between several days to up to two weeks prior to their emigration into the periphery. 
SP thymocytes are distinguished from mature peripheral T cells by their expression of heat-
stable antigen (HSA, CD24) and the concomitant lack of the non-classical MHC class I molecule 
Qa-2 on the cell surface (reviewed in (2)). While there is generally no reentry of naive T cells 
from the periphery to the thymus, a fraction of activated peripheral T cells appear to regain the 
capacity to home again to the thymic medulla (41). 
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Keratinocyte growth factor
Keratinocyte growth factor (KGF) is a member of the family of fibroblast growth factors. 
Also known as fibroblast growth factor-7 (FGF-7), KGF is a heparin-binding molecule that 
displays mitogenic activity, affects changes in cell morphology and controls the differentiation 
of several epithelial cell types. The KGF cDNA encodes a protein of 194 amino acids, which 
bears potential N-linked glycosylation sites (42). The area of highest homology between FGF-7 
and other FGF family members is within the carboxy-terminal two/third of the KGF coding 
sequence. 
KGF is expressed by mesenchymal cells and is typically detected during development in 
several anatomical sites including the ureteric bud, the urogenital sinus, the kidney rudiment, 
the external genitalia, the mammary glands, the thyroid and the thymus anlage (43). The 
most potent inducer of KGF expression in fibroblasts is the proinflammatory cytokine IL-1 
(44), which, in addition to TNF-α and IL-6 (45), plays a dominant role in the events leading 
to wound healing. However, in addition to mesenchymal cells, other cell types are also 
competent to express KGF. For example T cells of the γδ lineage isolated from either the skin 
or the intestine secrete KGF (46). Similarly, thymic T cells belonging the αβTcR lineage but 
representing different stages of development also express KGF under physiological conditions 
(47). In contrast to expectations based on the wide tissue expression of KGF, mice rendered 
completely deficient for the expression of this factor were described to develop normally but 
for the exception of having a greasy fur. The overt absence in these mice of developmental 
defects, of alterations in epithelial cell growth and of deficiencies in wound healing argues for 
the presence of other factors that signal in parallel and thus compensate for the loss of KGF 
(48). Indeed, there is substantial redundancy for KGF signaling as both in vitro studies with cell 
lines and in vivo investigations of gene targeted mice (see below) concluded that practically all 
KGF functions can also be effected by FGF-10 signaling which occurs via a receptor binding 
both KGF and FGF-10. 
Further insights into the biological role of KGF have been obtained by transgenesis experiments. 
Overexpression of KGF in skin fibroblasts resulted in a hypertrophy of the epidermis and 
hypoproliferation of keratinocytes (49), while overexpression of KGF directed to epithelial 
cells of the developing embryonic lung disrupted normal pulmonary morphogenesis (50). In 
these mice, the lung parenchyma was cystic and displayed numerous dilated saccules lined 
by columnar epithelial cells. Although mesenchymal cells are maintained in the transgenic 
mice where KGF was expressed under the transcriptional control of the surfactant protein C 
promotor, the architectural relationship between mesenchyme and epithelial cells was severely 
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altered. Yet in other transgenic mice hepatic overexpression of KGF resulted in high serum 
levels and caused changes in several tissues known to express the KGF specific receptor (51). 
The reported pathological changes included hepatocyte and biliary epithelial hyperplasia, 
pancreatic ductal hypoplasia, enhanced proliferation of bronchial epithelial and pneumocyte 
II cells, and kidney hypoplasia with cystic dilatations of the cortico and medullary collecting 
duct systems. Finally, overexpression of KGF under the control of the human insuline 
promotor resulted in the emergence of hepatocytes within the islets of Langerhans and caused 
the proliferation of intra-islet duct cells (52, 53). Thus, the precise temporal and spatial control 
of KGF expression is dominant in normal organogenesis as a consequence of mesenchymal-
epithelial signaling. 
The observation that KGF promotes proliferation of all epithelial cells along the mouse 
digestive tract initiated studies to use recombinant KGF in murine models of gastrointestinal 
injury as induced by radiation (54, 55), chemotherapy (55), or a combination of both (55). 
Treatment with KGF before and after injury resulted, in this model, in a remarkable reduction 
in the mortality rate when compared to appropriate controls (54). This finding was paralleled 
by both lesser weight loss following radiation and/or chemotherapy and faster weight gain 
during recovery (55). These clinically relevant changes may be accounted for by the trophic 
effect of KGF on gastrointestinal epithelium as the mucosal thickness increased significantly 
and crypt survival in the small intestine was enhanced by severalfold. Taken together, these 
findings have suggested that KGF may have a substantial therapeutic potential to lessen 
epithelial side effects secondary to injury by chemo-radiotherapy.
KGF receptor: FgfR2IIIB 
The receptors for Fgfs (FgfR) represent a family of transmembrane molecules which are 
encoded by four separate genes (FgfR1-FgfR4) and composed of either two or three Ig-like 
loops in the external domain, a transmembrane segment and a ligand-activated cytoplasmic 
tyrosine kinase domain. The two membrane proximal Ig-loops form the ligand-binding 
domain; receptor diversity is increased by alternative splicing which generates two distinct 
receptor forms for FgfR1, FgfR2 and FgfR3. Alternative splicing of the Ig-loop III generates 
two separate isoforms (IIIb and IIIc) that display distinct ligand-binding properties and 
tissues distributions (56-58). The FgfR2IIIb isoform constitutes the receptor where KGF binds 
preferentially and is typically, if not exclusively expressed on epithelial cells (43, 59). Thus, 
KGF exhibits a paracrine mode of action, as it is usually produced by cells of mesenchymal 
origin but acts on epithelial cells (10-13, 43, 59-65). In addition to KGF, the FgfR2IIIB is also 
activated by Fgf1, Fgf3, Fgf10, albeit each of these molecules displays a different affinity for 
this receptor. It is, therefore, not surprising, that mice deficient for KGF fail to display any 
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developmental pathology (48). To further investigate the biological role of FgfR2IIIb and to 
determine its developmental importance, receptor transgenic and gene-targeted mice have 
been generated. For example expression of a dominant negative FgfR2IIIb receptor in lung 
epithelium resulted in a complete block of airway branching and epithelial maturation leading 
to two undifferentiated tubes below the bifurcation of the trachea (66). In another model, the 
FgfR2 gene was altered in such a way that expressed receptors were devoid of the entire Ig-like 
loop III (67). About a third of the mutant mice failed to form the chorioallantoic fusion junction 
and the remaining mice did not have the labyranthine portion of the placenta secondary to a 
lack of trophoblast cell proliferation. Moreover, these mice did not develop limb buds thus 
providing direct genetic evidence that FgfR2 signalling is essential for limb formation. Loss 
of the IIIc ligand-binding exon, the transmembrane domain and the kinase I domain of FgfR2 
revealed that signalling through such a receptor was not possible and led to alteration in 
development at E4.5 to E 5.5 prior to the formation of the egg cylinder (68). To gain insight 
into a potential role of FgfR2IIIc signalling during development beyond implantation, fusion 
chimeras were constructed using homozygous mutant embryonic stem cells and wild-type 
tetraploid embryos. Although chimeric mice survived until the end of a regular gestation, 
the absence of normal FgfR2 activity did cause severe developmental defects in limb bud 
formation and lung development (69). 
KGF and the thymus
Several cell types of different developmental origin are responsible for the thymic production 
of KGF, including mesenchymal cells and thymocytes. However, it appears to be a matter of 
debate which specific subpopulation of maturing thymocytes expresses KGF. In a recent study 
by Erickson and colleagues (47), KGF transcription was detected by RT-PCR only in DP and 
CD4 SP thymocytes. In contrast, work by Min and colleagues (70) reported that KGF mRNA 
was present in all four major thymocytes subpopulations (TN, DP, CD4 SP and CD8 SP), as 
well as in thymic stroma cells. Nevertheless, the precise phenotypic nature of the latter cell 
was not further specified. In contrast, it is unanimously accepted that thymic epithelial cells 
(as defined by the presence of MHC class II but the absence of CD45) express the specific 
receptor for KGF, designated FgfR2IIIb (71). This observation is further corroborated by the 
detection of FgfR2IIIb expression on epithelial cells at all stages of thymic development as 
investigated by in situ hybridization (47). Interestingly, the strongest signals for FgfR2IIIb-
specific transcripts were detected in the medulla as well as the subcapsular region, two distinct 
areas that have previously been noted to share several phenotypic markers when analyzed by 
immunohistochemistry.
To detail a role for KGF in the formation of distinct compartments within the thymic 
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microenvironment, fetal thymic organ cultures (FTOC) were analyzed. Erickson and colleagues 
(47) tested whether the formation of the medulla is regulated by KGF, assuming that this factor 
would be provided by phenotypically mature thymocytes. Such a hypothesis is in keeping 
with observations that mice deficient in mature SP thymocytes also lack a regularly shaped 
medulla. Using T cell-depleted fetal thymic tissue from E16, ex vivo treatment with KGF failed, 
however, to generate a proper medullary foci, present in the control group, but the medullary 
compartment was more diffusely organized. These results, therefore, indicate that the in situ 
presence of KGF cannot replace yet unknown signals provided by developing thymocytes able 
to induce the regular medullary formation. However, in vivo treatment of Rag-deficient mice 
with KGF resulted in an increase in size of the otherwise diffuse medullary areas (47). The 
molecular and cellular mechanisms that account for this obvious discrepancy in the biological 
role of KGF in vitro versus in vivo treatment for the patterning of a thymic medulla has not 
been further addressed. It is, however, conceivable that KGF’s capacity to form a medulla is 
either dependent on a stimulation of extrathymic factors that act in concert with KGF or that 
KGF’s biological activities dependent on the concomitant presence of immature thymocytes. 
Further experiments will need to be carried out to address these points. In vitro exposure for 
48 hours of unmanipulated fetal thymic tissue to KGF resulted in a dose-dependent reduction 
in thymic cellularity and in a maturational impairment of CD4 SP thymocytes. Thus, KGF in 
the dosages given (10 ng/ml), during prolonged culture (15 days) and in the experimental 
system analyzed will also affect lymphoid development, albeit via an indirect mechanism as 
thymocytes do not express FgfR2IIIb (47). 
Hematopoietic stem cell transplantation and GVHD
In recent years, hematopoietic stem cell transplantation (HSCT) has become the therapy of 
choice for an expanding number of malignant and non-malignant diseases. The transfer of 
hematopoietic stem cells (HSC) from a donor to a genetically non-identical recipient is referred 
to as allogeneic HSCT. In contrast, the cell transfer between two genetically identical individuals 
is defined as syngeneic HSCT, while autologous HSC involves the use of the patient’s own 
HSC. Autologous HSCT has been successfully used in conjunction with chemotherapy for solid 
organ tumors (breast cancer and neuroblastoma, among others) and malignancies affecting 
mature cells of the lymphoid lineage (including non-Hodgkin lymphoma, Hodgkin’s disease, 
etc.), while allogeneic HSCT is favored for the therapy of different forms of leukemia (including 
acute and chronic myeloid leukemia and acute lymphoid leukemia), and for the treatment of 
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diseases affecting the functional 
production of hematopoietic cells. 
As demonstrated in Figure V 
(adapted from (72)), close to 20’000 
HSCT have been carried out in 
Europe in the course of the year of 
2001. One third of these transplants 
concerned the engraftment of 
allogeneic cells while 2/3 entailed 
the transfer of autologous cells. 
In the same year, 281 HSCT were 
performed in Switzerland alone 
and in comparison to the European 
practice, fewer of these transplants 
(28 %) used allogeneic cells.
Stem cell engraftment in the absence 
of transplant-related complications 
critically determines the outcome 
of HSCT. In particular, graft-versus-
host disease (GVHD), pulmonary 
dysfunction and veno-occlusive 
disease constitute major complications of allogeneic HSCT. In contrast, the recurrence of the 
original disease (an event also known as relapse) constitutes the most important complication of 
autologous HSCT. From an immunological point of view, a transient and frequently prolonged 
immunodeficiency follows both allogeneic and autologous HSCT and constitutes a particular 
medical challenge, as this complication correlates with the occurrence of disease relapse and 
life-threatening bacterial, viral or fungal infections. Initially caused by chemotherapy and/or 
total body irradiation that are used as pre-transplant conditioning regimen (see below), the 
slow recovery of the different hematopoietic cell lineages following HSCT constitutes a major 
reason for the prolonged persistence of a marked immunodeficiency. Importantly, lymphocyte 
recovery is significantly delayed in the presence of GVHD when compared to allogeneic 
recipients of an HSCT without this complication. Thus, GVHD significantly contributes to an 
extended and often exacerbated state of immunodeficiency (73). However, the precise cellular 
and molecular mechanisms that account for this GVHD-associated damage are still unknown. 
Their elucidation necessitates an increased understanding of the pathophysiological processes 
leading to this debilitating disorder. 
Figure V Main indication and donor type of HSC in europe 
2001.  a) Absolute numbers of HSCT by donor type and main 
indication. b) Relative proportion of donor type by main 
indication. Adapted from Gratwohl at al., 2002, Bone Marrow 
Transplantation.
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The basic requirements for GVHD
In the absence of effective immunosuppression, the outcome of most allogeneic HSCT will 
be complicated to various degrees by GVHD. Three independent requirements have been 
identified for GVHD to occur: (i) the graft contains a sufficient number of immunologically 
competent cells; (ii) donor and host are genetically different in that important transplantation 
isoantigens are present in the latter but lack in the former; and (iii) the host immune system 
is incapable of mounting an effective anti-graft response. Given these conditions, GVHD can 
develop in different clinical settings where tissues harboring immunocompetent cells are 
transferred across relevant histocompatibility differences (74). 
Genetic basis of acute GVHD
The major histocompatibility antigens encoded by the major histocompatibility complex 
(MHC) genetic loci exert the biggest impact on the immune system’s recognition of antigenic 
differences between donor and host (75). The MHC constitutes a highly polymorphic, multi-
gene and multi-allelic complex central to both cell-mediated and humoral immunity. The 
MHC molecules are cell surface proteins that present antigenic peptides to T cells and thus 
control the activation of effector cells of the adaptive immune system. Two different classes of 
MHC molecules have been defined based on structural and functional characteristics: Class 
I molecules are composed of the MHC-encoded polymorphic chain that harbors the antigen 
binding site and the invariant chain designated β2-microglobuline. The complete MHC class 
I complex is expressed on most nucleated cells. The MHC class II molecules are composed of 
two chains that are both encoded within the MHC locus. Combined, these two proteins form 
the antigen-binding site. Since MHC class II cell surface expression is particularly induced 
on skin and intestinal epithelium in the course of inflammation, it is not surprising that these 
anatomical sites serve as specific targets for alloantigen recognition during acute GVHD (76, 
77). Recognition of the allogeneic MHC is followed by ligation of adhesion molecules on T cells 
to their corresponding receptors on target cells. In order for the activation to occur, additional 
costimulatory signals are required as provided for example by interactions of CD28/B7, CD4/
MHC class II and CD8/MHC class I antigen (78-83). In consequence the correctly stimulated 
lymphocyte begin to acquire the cell surface expression of molecules such as CD25 (IL-2R), 
CD69 and CD71, which serve as ideal markers for recent cell activation. In parallel, primed 
T cells initiate the transcription of cytokines, which are essential for the differentiation, 
proliferation and amplification of the T cell (84-86).
Minor histocompatibility antigens (miH) represent genetically polymorphic peptides derived 
from intracellular proteins that are presented by either the host’s or the donor’s MHC 
molecules (87). Genetic polymorphism of endogenous cellular proteins represents the miH: 
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these molecules are critical in matched-sibling allogeneic HSC graft. T cells do not recognize 
antigen alone, but in conjunction with the MHC of the antigen presenting cells (88). In this 
context, miH constitute a relevant immunological difference in the transplantation of MHC-
matched allogeneic tissues. Following their activation, donor T cells mediate the tissue 
destruction known clinically as GVHD (see below).
Clinical and experimental studies have provided ample evidence that the severity of 
GVHD directly correlates with the number of donor T cells transfused (89). Based on these 
observations, T cell depletion (TCD) from donor bone marrow has prevented the development 
of both experimental and clinical GVHD (90). It is, however, of note that the presence of donor 
T cells in the allogeneic bone marrow graft exerts also the beneficial effect of an anti-tumor 
activity (also known in hematopoietic malignancies as graft-versus-leukemia (GvL)-effect) 
(91). Thus, depletion of T cells from the bone marrow inoculums as a measure to prevent 
GVHD increases the risk of leukemic relapse to a level similar to that observed in autologous 
HSCT. In keeping with the conditions for the occurrence of GVHD, this complication can 
also occur under conditions where recipients remain immunocompetent. Specifically, MHC 
heterozygous recipients will not reject tissues derived from donors that are homozygous for 
one of the recipient’s haplotypes. Such a condition of a P->F1 (parent into an F1 generation) 
transplantation is usually only given under experimental conditions. Given these experimental 
circumstances, the allogeneic donor T cells will recognize the recipient and will mediate an 
immune response leading to GVHD. 
Clinical, histopathological and immunological characteristics have been used to differentiate 
the course of GVHD into an acute and chronic disease phases. For practical purposes, GVHD 
occurring in allogeneic recipients within the first 100 days after transplantation is referred 
to as acute GVHD, while chronic GVHD is defined as a disease typically apparent only 100 
days post-transplantation. However helpful such a distinction may be, this”100-Days” rule 
is not always easily applied in clinical practice as acute GVHD (aGVHD) may indeed occur 
within days or may only be apparent as late as 1–2 months after HSCT. Moreover, clinical and 
histological changes considered characteristic for chronic GVHD (cGVHD) might develop 
as early as 40–50 days post-transplant and overlap with aGVHD. Hence, the time of disease 
onset constitutes only an arbitrary criterion to separate two pathophysiologically distinct 
forms of GVHD. Acute and chronic GVHD are, however, better separated in experimental 
models of HSCT. Chronic GVHD is characterized in the Parental -> F1 murine transplantation 
models by a reduction of cytotoxic lymphocyte (CTL) activity, the persistence of recipient T 
and B cells, a polyclonal B cell activation whit abnormal Ig secretion, the production of anti-
ssDNA antibodies and an immune mediated damage to the kidney, immunopathologically 
reminiscent of glomerulonephritis (92-97). In contrast acute GVHD is highlighted by anti-host 
22 23
CTL activity, an increase in donor CD8+ T cells, and NK cells, splenomegaly and lymphoid 
hyperplasia. Later in consequence of acute GVHD: splenic hypoplasia, cachexia, anaemia, 
general and specific immune suppression and epithelial cell damage are observed (98).
GVHD affects multiple organ systems and can thus account for severe morbidity and mortality 
following allogeneic HSCT. Principal targets of GVHD are the epithelial cells of skin, liver, 
gastrointestinal tract and thymus and the observed severity of pathology correlates with the 
number of T cells transfused with the donor HSC inoculum. The ensuing damage causes in 
the target organs programmed cell death of parenchyma cells and leads thus to a loss of organ-
specific functions. In the skin, both epidermis and hair follicles are frequently destroyed in 
the course of GVHD, leading to alopecia and inflammatory changes of the integument. In the 
liver, the small bile ducts are usually profoundly affected in GVHD, leading from segmental 
disruptions of the hepatic architecture to a complete failure of liver functions. Intestinal crypt 
destruction results in mucosal ulcerations that may either be locally defined or diffuse (99-103). 
Finally, thymic epithelial cells of both cortex and medulla appear to be targets of the process 
of alloantigen recognition, although a precise analysis of the subpopulation most affected by 
GVHD have not yet been reported. In addition to these T cell-mediated pathologies typical 
for GVHD, non-specific defects have also been observed to occur during a later phase of the 
disease, i.e. the development of a severe wasting syndrome, known as cachexia, generalized 
erythroderma with bullos formation and liver pathology marked by high bilirubin level.
The complex immunopathological events leading to acute GVHD are currently understood 
to be composed of an afferent and an efferent phase. The afferent phase of acute GVHD is 
caused by the immunosuppressive and therapeutic measures taken to prepare the recipient for 
HSCT. Known as conditioning, these treatments usually consist of total body irradiation (TBI) 
and/or high-dose chemotherapy. Both of these interventions cause also extensive damage to 
host tissues including intestine, skin, liver, and thymus. The ensuing pathology triggered by 
conditioning is mediated by inflammatory cytokines such as IL-1, TNF-α, GM-CSF, and INF-γ 
that is secreted by damaged host tissue (104, 105). These inflammatory molecules mediate the 
upregulation of adhesion molecules and cause the enhanced expression of MHC molecules on 
the respective target tissues of GVHD. These molecular changes increase, in turn, the allogeneic 
recognition of host tissue by donor T cells and thus lead to the efferent phase of GVHD, which 
is characterized by the activation of donor T cells upon recognition of host tissue antigens 
(106-109). Models of GVHD using defined inbred mouse strains have established that donor 
CD4+ T cells induce GVHD in the context of donor/host MHC class II differences while CD8+ 
T cells recognize in this context disparities between MHC class I molecules (104, 110). Under 
conditions where MHC identity exists between donor and recipient, differences in miH may 
suffice to trigger allorecognition via CD8+ cells leading to GVHD (107, 110). Activated donor T 
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cells exert their effect both via the release of proinflammatory cytokines as well as by a direct 
cytotoxic activity (see below). 
At least two independent signaling pathways need to be successfully engaged in order for T 
cells to be fully activated. The first signal is mediated as a consequence of the recognition of the 
MHC-peptide complex via the T cell antigen receptor (designated signal 1). The second signal 
is produced by the binding of antigen-unspecific co-stimulatory molecules on T cells to their 
respective ligands on antigen-presenting cells (see above) (110). 
One of the molecular events necessary for successful T cell activation is the expression and 
secretion of IL-2. This cytokine controls the clonal expansion of activated donor T cells and 
contributes to the differentiation of these cells into effector cells that secrete soluble mediators 
of inflammation (111, 112). For example the provision of IL-2 and IFN-γ primes donor as well 
as residual host mononuclear phagocytes to produce TNF-α, IL1 and nitric oxide (108, 113). 
The additional release of inflammatory cytokines by mononuclear phagocytes may, however, 
occur only in the presence of a second triggering signal such as bacterial endotoxines (LPS). 
These microbial products gain access through a damaged intestinal mucosa and activate gut-
associated lymphocytes and macrophages. The concentration of LPS needed to trigger a robust 
response by macrophages is significantly lowered if the macrophages have been previously 
primed by IFN-γ. Thus IFN-γ and LPS work synergistically in priming of naive macrophages to 
contribute to infiltration damage via their release of TNF-α and NO (114, 115). Thus, the tissue 
destruction during GVHD is generated by two independent mechanisms that act efficiently in 
concert: (i) direct cell-mediated cytotoxicity effected by both cytotoxic T lymphocytes (CTL) 
and natural killer (NK) cells; (ii) provision of soluble inflammatory mediators. Moreover, there 
is increasing evidence that a differential activation of either “T helper 1” cells (Th1) or “T 
helper 2” cells (Th2) will preferentially determine either of the two detailed pathways leading 
to phenotypically distinct forms of GVHD (see below) (108, 116).
Immunodeficiency as a consequence of GVHD
Although immunodeficiency following HSCT may be caused by several mechanisms, 
research in recent years has started to provide detailed insight into the cellular and molecular 
pathogenesis of this disorder. Following the conditioning-related elimination of the peripheral 
T cell pool, both extrathymic and thymic pathways of T cell development contribute to the 
reconstitution of the peripheral T cell compartment following HSCT (117-119). The first 
pathway concerns the clonal expansion of mature donor-derived T cells whereas the second 
pathway relies on the thymic output of de novo generated, HSC-derived mature T cells. While 
the mechanisms of peripheral donor T cell expansion fail to renew the T cell antigen receptor 
repertoire, it is the process of thymic T cell generation that assures the maintenance of a 
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broad specificity of the T cell antigen receptor repertoire over time. The relative contribution 
to each of these different pathways depends on thymic function and the number of donor-
derived mature T cells transfused with the HSC inoculums (120, 121). The presence of GVHD 
affects either pathway and thus exacerbates and prolongs the state of immune deficiency in 
the post-transplant period (122, 123). In addition, the rapid disappearance of host lymphoid 
cells during GVHD in a non-conditioned experimental model of HSCT is a consequence of 
an elimination of these host cells by mechanisms involving either perforin- or Fas-mediated 
killing (123-125). 
In the presence of GVHD, there is an obvious lack of the infused mature donor T cells bearing 
specificity for antigen other than alloantigens to functionally contribute to peripheral T cell 
function. The precise pathogenesis for this phenomenon is not yet known. However, depletion 
and functional loss of donor T cells have as a likely explanation been proposed. For example, 
activation-induced cell death of allo-reactive donor T cells may lead to bystander apoptosis 
of grafted T cells devoid of host reactivity (124). Alternatively, but not mutually exclusive, 
is a mechanism by which non-host specific donor T cells fail to respond to specific antigenic 
or mitogenic stimuli secondary to their severely skewed T cell antigen receptor repertoire 
following homeostatic expansion in a lymphopenic host (124). Moreover, antigen-non-
specific suppression of both B- and T cell reactivity may be the consequence of an exposure 
to suppressive cytokines (e.g. IFN-γ, TNF-α) and immunosuppressive molecules (e.g. NO) 
provided by the tissue of conditioned recipients (108, 126-128). As previously mentioned, the 
production of these soluble mediators is upregulated in the course of GVHD as a consequence 
of donor T cell activation. In addition, enhanced levels of IL-1-triggered glucocorticoid 
secretion may also contribute in this context to peripheral T cell suppression (115). While it 
may be attractive to assume that increased levels of serum glucocorticoid concentrations may 
have a deletional effect on immature thymocytes, recent data derived from experiments in 
the mouse provide evidence to the contrary since thymic pathology observed during acute 
GVHD is mediated by a mechanism of apoptosis independent of glucocorticoids (129). Finally, 
the disruption of the peripheral microenvironmental niches necessary for the expansion of 
post-thymic T cells may constitute another factor contributing to the immunodeficiency in the 
presence of GVHD (120). 
The reconstitution of a normal T cell antigen receptor repertoire determines the success of 
allogeneic bone marrow transplantation and is critically dependent not only on the clonal 
expansion of mature donor-derived T cells, but also on the swift re-establishment of a regular 
thymic function. However, two separate mechanisms account for the loss of regular thymic 
function in the presence of GVHD. First, a decreased self-renewal capacity of the most immature 
intrathymic T cell precursors has been observed in the presence of GVHD and may persist for 
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several months after HSCT engraftment. Since alloreactive T cells and HSC derive from the 
same donor, mechanisms other than the direct recognition of alloantigens will have to account 
for this functional alteration. Second, a direct damage to the thymic microenvironment impairs 
T cells maturation and selection because the thymus serves as a direct target of GVHD. 
Thymic pathology in GVHD
The thymus has been identified as a primary target for GVHD for almost 30 years (122). 
A comprehensive understanding of the molecular and cellular basis of GVHD-mediated 
pathology to the thymus is, however, still missing. Different animal models have unequivocally 
demonstrated a common pattern of structural changes to the thymic tissue as a consequence 
of allo-antigen disparity between host and donor in HSCT: decrease in thymic size, depletion 
of the cortex, loss of the CMJ, medullary epithelial cell necrosis, and loss of Hassall’s bodies 
(130, 131). 
Moreover, a slow regeneration of the thymic architecture has been observed in non-lethal 
models of GVHD that are dependent or independent of irradiation for preconditioning. The 
reparative mechanism required for thymic reconstitution may need as much as 6 months to 
complete. However, this repair is not necessarily paralleled by a regained regular function, an 
impairment may last for an extended period of time (131-134).
The mechanisms by which conditioning and GVHD induce the profound changes to thymic 
architecture and function have not yet been fully elucidated. It is conceivable that the following 
candidate mechanisms, either alone or in concert, may contribute to the observed pathology. 
(i) Thymic epithelial cell function is severely affected by the damaging effects 
of γ-irradiation (135). In addition to impaired thymic stromal function (136), 
γ-irradiation also upregulates Fas (137) cell surface expression, enhances 
extrathymic T cell development (138), and triggers the release of inflammatory 
cytokines (116).
(ii) The thymic infiltration of donor-derived allo-reactive T cells and the 
enhancement of host NK activity constitute common features of acute GVHD 
and may be responsible for the direct cytotoxic destruction of thymic stromal 
tissue (139-141). Indeed, acute GVHD has been associated with changes in the 
composition and architectural organization of thymic stromal cells (71).
(iii) A profound decrease of thymocytes (in particular DP cells) has been noted in 
acute GVHD. Two independent mechanisms may account for this apparent 
lack: (i) DP cells and their immediate precursors (TN cells) display a decreased 
capacity to enter into cell cycle, and (ii) DP thymocytes undergo programmed 
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cell death at an increased frequency in the presence of GVHD (142). 
Both of these mechanisms may be a consequence of altered thymic epithelial cell 
function. Thus, reduced proliferative capacity and an increased susceptibility 
to apoptosis account for the reduced number of thymocytes. 
(iv) GVHD affects thymic T cell antigen repertoire selection and is associated 
with the emergence of T cell clones with a “forbidden” T cell antigen receptor 
specificity. Moreover, the loss of normal thymic selection and the consequential 
persistence of autoreactive T cells have been related to the transition of acute 
GVHD to a more chronic form of the disease (143, 144). 
A growing number of reports have identified the importance of a regular thymic function 
and the selection of a broad repertoire of T cell antigen receptor specificities for the successful 
outcome of HSCT (118, 145-147). While these parameters may clearly constitute an important 
goal for clinical practice, the therapeutic measures to attain this aim have yet to be fully be 
defined. It is, therefore, informative to analyze in depth the cellular and molecular mechanisms 
that interfere with normal thymic T cell development in the presence of GVHD, as this 
understanding will provide insight into novel strategies to prevent, reduce or repair GVHD-
associated pathology to the immune system.
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Aim of the thesis
The aim of this thesis is to detail the biological role of KGF on thymic epithelial cell 
homeostasis and function under physiological conditions and in instances of epithelial cell 
damage secondary to GVHD. For this purpose different models have been employed to detect 
the molecular events triggered by KGF signaling. In particular I studied the following issues: 
I) identification of the cells within the thymic microenvironment that express the receptor 
specific for KGF, FgfR2IIIb, II) analysis of the response to KGF signaling by thymic epithelial 
cells at the cellular and molecular level, III) assessment of the role of KGF in the prevention/
repair of tissue damage to thymic epithelial cells in the course of GVHD.
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Materials and Methods
Animals
C57BL/6 (B6, H-2b), and [C57BL/6 x DBA/2] F1 (B6D2F1, H-2
bxd) mice were obtained from 
Iffa Credo (Charles River, France), and from a breeding colony at the University Hospital, 
Basel, Switzerland. The C57BL/6 congenic mouse strain B6.SJL-PtprcaPep3b/BoyJ (Ly5.1) 
was obtained from The Jackson Laboratories, ME, USA. Mice were housed in a pathogen-free 
facility. All animals were kept in accordance with Swiss guidelines and regulations. Female 
mice used for this study were between 4 and 10 weeks of age.
Reagents
For four-color flow cytometric (FACS) analyses, the following moAbs (conjugated to biotin, 
FITC, PE or CyChrome) were used: anti-CD3 (clone 145-2C11), anti-CD8 (53-6.7), anti-CD4 
(RM4-5), anti-TCRβ (H57-592), anti-CD44 (clone IM7), anti-CD25 (PC61), anti-Ly5.1 (CD45.1; 
A20), and anti-CD16/CD32 (2.4G2) (Pharmingen, San Diego, CA), Streptavidin-Tricolor 
(Caltag, Burlingame, CA) and Streptavidin-Cy5 (Zymed Laboratories, San Francisco, CA). 
FITC-conjugated anti-BrdU moAb (3D4) was purchased from Becton Dickinson (Mountain 
View, CA). For immunohistology, polyclonal rabbit anti-cytokeratin-5 Ab (Progene GmbH, 
Heidelberg, Germany), biotinylated mouse anti-cytokeratin-18 moAb (Ks 18.04, Progene 
GmbH, Heidelberg, Germany), biotinylated UEA-1 lectin (Vector Laboratories, Lausanne, 
Switzerland), MTS10 (Pharmingen, San Diego, CA), rat anti-MTS24 (supernatant, generous 
gift of R. Boyd, Melbourne, Australia), polyclonal rat anti-FGFR2 Ab (unpublished; a generous 
gift from Dr. Sabine Werner, Zürich, Switzerland) and rat IgG2a anti FGFR2IIIb (R&D System, 
Minneapolis), biotinylated anti-CD80-moAb (16-10A1, Pharmingen, San Diego, CA), were 
used. The medullary thymic epithelial cell line mTEC2-3 was a gift from Dr. M. Kasai (Tokyo, 
Japan).
Graft-versus-Host Disease induction 
The transplantation model used has been previously described in detail (142). In brief, acute 
GVHD was induced by transplantation of non-irradiated B6D2F1 mice (Ly5.2; H-2
bxd) with 25 
x 106 unseparated parental C57BL/6 splenocytes (Ly5.2+; H-2b), or with congenic B6.CD45.1 
(Ly5.1+; H-2b) cells. Donor cells were administered in a volume of 400 µl HBSS (Gibco) via 
tail vein injection. Syngeneically transplanted mice (B6D2F1−>B6D2F1) served as non-GVHD 
controls and received 25 x 106 donor splenocytes.
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KGF treatment 
KGF treatment in normal mice
C57BL/6 mice were injected i.p. for a period of 3 days with HBSS (Hank’s balanced salt 
solution) or recombinant human KGF (rhKGF; solubilized in HBSS) at a dose of 5 mg/kg 
per day. rhKGF was produced in E.coli and had an ED50 of 40.02 ng/ml (kindly provided by 
Amgen, Thousand Oaks, CA, USA). 
KGF treatment in the GVHD setting
B6D2F1 mice were injected i.p. for a period of day –3 to +3 after induction of GVHD (day 0) 
with HBSS (Hank’s balanced salt solution) or recombinant human KGF (rhKGF; dissolved in 
HBSS) at a dose of 5 mg/kg per day. 
Flow cytometric analysis
Cell surface marker analysis
Cells suspension from different organs (0.5-1x106) were washed, resuspended in 2% FCS/
PBS/sodium azide and incubated for 15 min at 4°C with unlabeled 2.4G2 moAb to prevent 
unspecific binding of the Fcγ receptors. For three-color flow cytometry, cells were first stained 
with fluorochrome- and biotin-conjugated moAbs and were subsequently labeled with 
Streptavidin-fluorochrome-conjugated (BD-Pharmingen, Basel or Zymed Laboratories, San 
Francisco, CA). To exclude dying cells from the analysis 7.5 μg/ml of Propidium Iodid was 
added to the ready to be analyzed cells. Analysis was performed using a two-laser FACS 
Calibur (Becton Dickinson, Mountain View, CA). 
Analysis of cell proliferation in vivo 
Mice were injected i.p. with 5’-bromo-2’-deoxyuridine (BrdU; 1 mg in 0.2 ml PBS; Sigma, 
Buchs, Switzerland) three and one hours for thymocytes analysis, 48 and 24 hours for thymic 
epithelial cells analysis before the initiation of the experimental analysis. Thymi were isolated 
and DNA-synthesizing cells were detected by four-color flow-cytometry, as described 
previously (142). Thymocytes (1x106) were stained with a mixture of CyChrome-conjugated 
anti-TcRβ, -CD8, -CD4 moAbs, PE-conjugated anti-CD44 moAb and Biotinilated anti-CD25 
moAb for 30 min on ice. Cells were then washed and incubated with Streptavidin-Cy5 for 15 
min. Cells were subsequently permeabilized with ice-cold 0.15M NaCl/95% ethanol for 30 
min at 4°C and fixed for another 30 min at room temperature in 1% Paraformaldehyde/PBS 
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with 0.01% Tween. Cells were then treated with 50 U/ml DNAse I in a 0.15 M NaCl/4.2mM 
MgCl2 -buffer for 10 min at room temperature. After washing, cells were stained with FITC-
conjugated-anti-BrdU moAb for 30 min at room temperature. Washed cells were analyzed 
using a FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA).
Detection of donor/host chimerism 
To discern donor-derived T cells (Ly5.1+) from host T cells (Ly5.2+), thymocytes and splenocytes 
were isolated from transplanted and control mice and stained with anti-CD45.1 moAb.
Cell separation
Freshly isolated thymocytes were stained with the appropriate moAbs and then sorted into 
CD4-CD8-, CD4+CD8+, CD4+CD8- and CD4-CD8+ subpopulations with the use of a FACS-
Vantage cell sorter (Becton Dickinson, Franklin Lakes, NJ, USA). For thymic epithelial cells 
isolation thymic lobes were separated and small cuts were made. Thymic lobes were then 
stirred two times in fresh IMDM-2 (IMDM+2% FCS) for 30 min in ice. The thymic lobes were 
transferred in new tubes containing Collagenase IV 1mg/ml+ DNAse 10mg/ml in IMDM-2 
and digested at 37°C for 15 min; every 7 min the suspension was mechanically disturbed. After 
mechanical disruption of the lobes done with a cut glass pipette the supernatant containing 
thymocytes was discarded and new Collagenase IV 1mg/ml+ DNAse 10mg/ml in IMDM-2 
was given to the thymi. After three round of digestion all supernatant was carefully discarded 
and fresh Collagenase IV 1mg/ml+ DNAse 10mg/ml in IMDM-2 was used for the last 
digestion round. Thymic lobes were suspended using needle with different diameters and 
the cell suspension was carefully washed in FACS buffer with 5 mM EDTA before starting the 
staining procedure. Adherent cells were stained with a combination of anti-IAb (MHC class II) 
and CD45 moAbs. IA+CD45- cells were sorted on a FACSvantage (Becton Dickinson, Franklin 
Lakes, NJ, USA).
Early thymic emigrants detection
C57BL/6 anesthetized mice were injected in one thymic lobe with 10 μl of FITC (Sigma, 
Buchs, CH) 125 μg/ml diluted in PBS (Stock solution 1mg/ml). 16 hours later the mice were 
sacrificed; thymus, lymph nodes and spleen were dissected and cell suspension was analyzed 
for the presence/absence of FITC+ lymphocytes (CD3+, CD4+ or CD8+).
Histopathology and immunohistology
For detection of FgfR2 and CD80 surface expression, thymi were isolated and embedded 
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in OCT (Tissue-Tek, Sakura Finetec, Netherlands). Frozen samples were cut into 6 µm 
thick sections, fixed with 4% paraformaldehyde/PBS and stained with biotinylated anti-
FgfR-2 or anti-CD80 antibodies for one hour. After washing, sections were incubated with 
streptavidin-conjugated horseradish peroxidase. Sections were then incubated with AEC and 
counterstained with hemalaun. For analysis of thymic morphology, sections were stained with 
hematoxylin and eosin.
Panels of antibodies and lectins have previously been used to characterize different 
thymic epithelial cell subsets. In brief, thymic epithelial cell subsets were identified using 
combinations of anti-cytokeratin 18 moAb and UEA-1 lectin, polyclonal anti-cytokeratin 5 
antibody and the epithelial cell-specific MTS-10 antibody. The particular staining protocol was 
adapted from Klug and coworkers (28) and is listed in more detail in Table 1. Two- and three-
color immunoflourescent sections were analyzed using a confocal microscope (Carl-Zeiss AG, 
Feldbach. Switzerland).
Fetal thymic organ culture (FTOC) analysis
Fetal thymic organ culture
From C57BL/6 mice embryo E15.5, thymic lobes were isolated and put in culture on Track-
Etch Membrane (Nucleopore #PC MB 13 mm, 0.8 mm pores, boiled in water for 30 min and 
kept sterile) in presence of 2’-deoxyguanosine (2-dG) at 1.35 mM in IMDM-10 (10% FCS). The 
fetal thymic lobes were incubate for 6 days in presence of 2-dG, 37°C, 7.5% CO2; complete 
thymocytes depletion is achieved. After this point the lobes were washed and starved 
24h in IMDM-1 (1%FCS), after starvation the lobes were stimulated with different rhKGF 
concentration for 24h or longer: than washed. After stimulation I performed different type of 
analysis:
Table 1. Phenotypic analysis of TEC using antibodies again cytoker-
atins (CK) and the cell surface molecule MTS10 as well as binding 
of the lectin UEA-1.
CK18 CK5UEA-1 MTS10
Major cortical TEC
Minor cortical TEC
and CMJ
Major medullary TEC
Minor medullary TEC
+
+
+ +
+
+ +
TEC subpopulations
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Proliferation assays 
I add 3H-Thymidine for different times and lobes were then digested with 1xTrypsin/EDTA at 
37°C for 30 min. Cells were harvested onto a DNA filter (Printed Filtermat A, Wallac) using a 
Micro 96TM harvester (Skatron Instrument Inc.). After amplification with scintillation fluid, the 
signal from 3H-labeled DNA was detected with a beta counter (C1205 Beta Plate-CounterTM, 
Wallac).
Reconstitution and phenotype analysis 
Fetal liver stem cells were isolated from fetal liver, day 14.5 fetuses. 2.5-5x104 fetal liver cells in 
IMDM-10 were incubated in a Terasaki-plate well together a depleted fetal lobe for 24 hours. 
After this period the lobes were incubated back on a Track-Etch Membrane in IMDM-10 for at 
least 20 days and then thymocytes phenotype and thymic epithelial phenotype were analyzed 
using flow cytometry.
Stimulation and RNA extraction
Depleted thymic lobes were washed and starved o/n in IMDM-1, than stimulated with 
different factors at different concentrations: - KGF 100 ng/ml (Amgem, Thousand Oaks, 
CA, USA), - NFkB inhibitor (PS1145) 10 μM (*), - FTase inhibitor (L-778,123) 1 μM (*), - FTase 
inhibitor (L-779,575) 1 μM (*), - GGTase inhibitor (L-841,491) 10 nM (*), - Fgf20 100 ng/ml (*), - 
p53 inhibitor 10 μM (*). (*: Generous gift of B. R. Blazar, Minneapolis). Stimulation was carried 
out for 24 hours and than RNA was isolated.
Isolation of mouse tissue RNA and cDNA synthesis and PCR
RNA isolation
Frozen thymic tissues or frozen cell suspensions were suspended in 1 ml TRI-reagent 
(Molecular Research Center Inc.) and homogenized with a Polytron homogenizer (Kinematica 
PT 1200) for approximately 30 sec with increasing speed and all samples were incubated 10 
min at room temperature. To extract the aqueous phase, 100 µl (1:10) bromochloropropanol 
(Molecular Research Center Inc.) was added. Samples were shaken for 10 sec and incubated 
for another 10 min at room temperature. The samples were centrifuged at top speed in a 
tabletop microcentrifuge (Eppendorf) at 4°C for 10 min. The aqueous phase was transferred 
to another Eppendorf tube and precipitated for 1 hour at room temperature with an equal 
volume of isopropanol (Sigma, Buchs). The samples were centrifuged again at top speed at 
4°C for 30 min. The liquid was carefully aspirated and the pellet was resuspended in 1 ml 75% 
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ethanol, vortexed and centrifuged at top speed at 4°C for 10 min. The liquid was aspirated as 
much as possible and the pellet was dried. The pellet was then dissolved in 30 μl H2O and the 
total RNA concentration was measured with a Gene-Quant machine II (Pharmacia Biotec). 
cDNA synthesis from total RNA
To obtain cDNA, total RNA samples (4 μg) were mixed with 18 μl H2O containing 500 μM 
dNTP, 10 mM DTT, 1 μl DNAse I and 1 µl of 1x1st strand buffer. This mixture was incubated for 
30 min at 37°C. After the incubation, the oligo dT20 primer was added at a final concentration of 
500 nM and the mixture was heated for 5 min at 70°C. The samples were quickly centrifuged at 
room temperature. Thereafter, 200 units of Moloney Murine Leukemia Virus (MMLV) reverse 
transcriptase was added and the samples were incubated at 42°C for 1 h. The reaction was 
quenched for 5 min at 95°C and then the samples were diluted in aliquots at a concentration of 
20 ng/μl and stored at –70°C. All buffers are from Gibco BRL, Basel, CH.
Polymerase chain reaction (PCR)
For end-point PCR analysis of FgfR2IIIb mRNA expression, total RNA was isolated from whole 
thymic tissue, freshly isolated thymic epithelial cells, established thymic epithelial cell lines or 
thymocyte subpopulations (where indicated) were isolated. After reverse transcription, the 
cDNA was amplified for 38 cycles. 
For quantitative PCR analysis, total RNA was isolated from unseparated thymic tissue at day 
13 after transplantation. RNA was reverse transcribed and the resulting cDNA was amplified 
in a total volume of 25 µl buffer containing 20 ng cDNA, 1 x SYBR Green ™ PCR Master 
Mix (PE Biosystems, Rotkreuz, Switzerland), and 300 nM forward and reverse primer each. 
Primers for real-time PCR were designed according to published mouse RNA sequences. As 
an internal reference for thymic epithelial cells, the gene for the epithelial V-like antigen (EVA) 
(148) was amplified, whereas GAPDH or S18rRNA was used as an internal reference for all 
cells. The cycle conditions were: 50°C for 2 min followed by 95°C for 10 min, after which 40 
cycles of amplification were carried out (95°C for 15 sec, 60°C for 1 min). The PCR reaction 
was performed in a GeneAmp 5700 SDS Real Time PCR machine (AB Applied Biosystems). 
Samples were analyzed in triplicates, and the result was averaged. 
Primers used 
Mip-1b: sense TGCTCGTGGCTGCCTTCT, 
anti-sense CAGGAAGTGGGAGGGTCAGA; 
Mip-1a: sense TTTTGAAACCAGCAGCCTTTG, 
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anti-sense TCTTTGGAGTCAGCGCAGATC; 
TECK: sense CAGCACAGGATCAAATGGAATG, 
anti-sense GGTTGCAGCTTCCACTCACTT; 
IL7: sense GGGAGTGATTATGGGTGGTGAG, 
anti-sense TGCGGGAGGTGGGTGTAG; 
Aire: end point PCR sense GGTTCTGTTGGACTCTGCCCTG, 
anti-sense TGTGCCACGACGGAGGTGAG; 
Granzyme B: sense GACCAGCTCTGTCCTTGGCA, 
anti-sense ATGTCAGTTGGGTTGTCACAGC; 
CD80: sense GAGTCTGGAACCCATCTGCA, 
anti-sense GAAGCGAGGCTTTGGGAAAC; 
KGFR: sense CACTCGGGGATAAATAGCTC, 
anti sense GTCCTTCTCTGTGGCATCAT.
IL7: real time sense GAAGACCCAGCGCAAAGTAGA, 
anti-sense CACGCCTGGTCCATCCAT    
IL7R: real time sense AGGCCTCCTGTGTATCAAG, 
anti-sense GACATGGTGACATACGCTTCT
Shh: real time sense GGAACTCACCCCCAATTA, 
anti-sense TGCTCGACCCTCATAGTGTA
Wnt4: real time sense ACCCAAAAACCAAACCAAAACA, 
anti-sense GTGGCTGCAGGTTCCACTG 
Wnt5b: real time sense AGGAAGTTGGCTGCACACG, 
anti-sense CCGCTTTGGAAGATGTTGGT
Wnt10b: real time sense TCCTCCACTACAGCCCAGAACCT, 
anti sense TTATCCATTCCCGCCCTTCCT
BMP2: real time sense ATGACTGGATCGTGGCACCT, 
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anti sense BMP2 CAGCATGCCTTAGGGATTTTG
BMP4: real time sense AAGAACTGCCGTCGCCATT, 
anti sense TGGCATGGTTGGTTGAGTTG
AIRE: real time sense CCAGTGAGCCCCAGGTTAAC, 
anti sense GACAGCCGTCACAACAGATGA
FoxN1: real time sense AACAGGCAATGAGGCAGGTG, 
anti sense TAGAGAGTGCTGAGGTGCATGTC
The transcript expression was normalized to:
S18rRNA: real time sense CGCTATTGGAGCTGGAATTACC, 
anti sense GCCCTGTAATTGGAATGAGTCC
GAPDH: real time sense ACCATGTAGTTGAGGTCAATGAAGG, 
anti sense GGTGAAGGTCGGTGTGAACG
EVA: sense GTGCCGCCTGCTCGTC, 
anti-sense CCGAACATCTGTCCCGTTGA
Statistical analysis 
Groups were compared by one-way ANOVA. Where ANOVA revealed a significant difference, 
the Bonferroni/Dunn post hoc test was performed. The overall statistical significance level 
was set to 5%. 
For 2 groups comparison where the data were not “Gaussian”-distributed the Mann-
Whitney test was used.
StatViewTM from SAS Institute Inc. was used for statistical analysis.
36 37
Results
The effect of KGF on thymic epithelial cells
Thymic epithelial cells are crucial for the complex events of T cell development as these cells 
control both proliferation and differentiation of thymocytes. This capacity is shared to various 
degrees with other stromal cells such as dendritic cells, macrophages and thymic fibroblasts. 
Damage by radiation, chemotherapy, or T cell-mediated allo-recognition may, therefore, 
severely affect both composition and function of the thymic stromal cells and may promote 
changes in normal thymic function. Thus, the protection of the thymic stroma in general and 
of thymic epithelial cells in particular may specifically prevent the loss of thymic function in 
the context of HSCT. 
In view of this documented protective role for epithelial cells of the intestine and the lungs, 
KGF may also exert a beneficial effect on thymic epithelial cells. In a first series of experiments, 
the effect of KGF was, therefore, tested on thymic epithelial cells of unchallenged, healthy 
mice. In a second series of experiments, a murine transplantation model was investigated 
where the transfer of haploidentical T cells results in severe thymic pathology affecting both 
lymphoid and stromal cells. 
The receptor for KGF, FgfR2IIIb, is expressed on thymic epithelial cells but not on thymocytes
A beneficial effect of KGF on 
thymic T cell development 
may either be effected directly 
through binding of KGF to its 
specific receptor expressed on 
thymocytes or, alternatively, may 
be accomplished indirectly by 
stimulation of thymic stromal cells. 
To define the thymic target cell(s) 
of KGF activity, thymocytes at all 
maturational stages and thymic 
epithelial cells were analyzed by 
end-point RT-PCR for transcripts 
Figure 1 Detection of FgfR2IIIb specific transcripts in unsepa-
rated thymic tissue, purified thymocytes at distict stages of 
development, freshly isolated thymic epithelial cells and an 
established medullary epithelial cell line.
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specific for FgfR2IIIb, also known as KGF receptor (KGFR). As demonstrated in Figure 1, 
transcripts for FgfR2IIIb were exclusively detected in freshly isolated thymic epithelial cells 
(as defined by the cell surface expression of MHC class II and by the lack of CD45 positivity) 
and in an established thymic medullary epithelial cell line (mTEC 2-3) ((149)). In contrast, none 
of the purified thymocyte subpopulations harbored mRNA specific for FgfR2IIIb. The selective 
detection of transcripts for the receptor in thymic epithelial cells but not cells of hematopoietic 
origin was further ascertained using immunohistology. For this purpose, a polyclonal 
antibody was used that had been raised against YDINRVPEEQMTFKDLVS peptide and that 
specifically recognizes all splice variants of FgfR2 (S. Werner, personal communication). As 
demonstrated in Figure 2, epithelial cells but not 
thymocytes stained positively with this antibody 
that also recognizes the FgfR2IIIb splice variant. 
Specific signals were abundant in the medulla 
where thymic epithelial cells form a tight cellular 
meshwork. In contrast, positive staining was sparse 
in the cortex, a finding, which is in keeping with 
the relatively low abundance of epithelial cells in 
this anatomical compartment. Taken together, these 
results demonstrate that FgfR2IIIb is selectively 
expressed on epithelial cells within the thymus. 
The cellular composition and architecture of the 
thymic epithelial cell compartment has been noted 
to be critical for normal function. It is for this reason that the influence of KGF on the thymic 
stromal composition and organization was investigated in treated mice. Thymic epithelial cells 
can be phenotypically differentiated into four distinct subpopulations based on binding of 
UEA-1 lectin and the use of antibodies that characterize cell surface antigen designated MTS-
10, cytokeratins 
(CK) 5 and 18: 
(i) major cortical 
thymic epithelial 
cells (CK18+, 
CK5-, UEA-1-, 
MTS-10-), minor 
cortical thymic 
epithelial cells 
(CK18+, CK5+), 
major medullary 
Figure 2 Expression of FgfR2 on thymic sec-
tion. Arrow: expression of FgfR2 on cortical 
epithelial cells. C: cortex. M: medulla.
Thymus: Saline injected mouse Thymus: KGF injected mouse 
Figure 3 KGF treatment does not modify thymic architecture of cortex and me-
dulla. HE staining of thymic sections; C:cortex, M: medulla, CMJ: cortico-medul-
lary junction.
M
M
C
C
CMJ
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thymic epithelial cells 
(CK5+, MTS-10+), and 
minor medullary thymic 
epithelial cells (CK18+, 
UEA-1+) ((28)) (see Table 
1). For the phenotypic 
analysis of the thymic 
epithelial stroma, mice 
were injected with KGF 
for three consecutive 
days at a dose of 5 mg/
Kg/day and thymic 
tissue was removed two 
weeks later, frozen in OCT and processed for immunohistology. Comparing thymic tissues 
of mice treated with KGF or, alternatively, with HBSS (Saline control), revealed the same 
results in the make-up and architectural organization of the epithelial compartment (Figure 
3). Thus, in vivo treatment with KGF did not qualitatively alter the epithelial stroma and its 
microenvironmental organization (Figure 4). However, thymic cellularity had doubled in 
response to KGF treatment (see below) although the relative distribution of thymocytes into 
the four distinct subpopulations characterized by the differential expression of CD4 and CD8 
remained unaffected (Figure 5). Taken together, these results demonstrate that in vivo treatment 
with KGF increases thymic cellularity in a proportional fashion affecting both stromal as well 
as lymphoid cell lineages.
Next, the FgfR2IIIb expression on thymic epithelial cells was analyzed by confocal microscopy 
Figure 4 KGF does not alter the phenotype nor composition of thymic 
epithelium.
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Figure 5 KGF doubles the thymic cellularity in 15 days, but does not alter the phenotype nor composi-
tion of CD4/CD8 thymocytes.
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and related to the expression of epithelial cell-specific markers detailing either a cortical or a 
medullary phenotype. As demonstrated in Figure 6, the expression of FgfR2IIIb could be co-
localized to MTS24+ cells, a population of epithelial cells known for its potential to serve as a 
precursor to all thymic epithelial cell types. In addition, all UEA-1+ cells expressed also the KGF 
receptor (Figure 6b). In contrast, only a small proportion of CK5+ medullary epithelial cells were 
also positive for the presence of FgfR2IIIb, and among those, an even smaller fraction of cortical 
epithelial cells stained positively for the expression of this receptor (Figure 6c and d). Finally, 
a small population of minor cortical epithelial cells expressing concomitantly the cell surface 
markers CK5 and CK18 were positive for FgfR2IIIb expression. Taken together, the receptor 
specific for KGF is expressed on medullary epithelial cells and on a small subpopulation of 
major and minor cortical epithelial cells. Moreover, all cells with the phenotype of the putative 
thymic epithelial stem cell also express FgfR2IIIb. 
KGF induces in vitro the proliferation of a thymic epithelial cell line
KGF has been noted to act as a mitogen on keratinocytes (150). To assess a similar effect of 
KGF on thymic epithelial cells and to correlate a possible increase in thymic cellularity to 
KGF-mediated cell proliferation, established thymic epithelial cell lines were first tested 
in vitro for their proliferative response to KGF. For this purpose, the thymic epithelial cell 
lines TEM 2.3 and C6 were grown in 96 well plates to semi-confluence and subsequently 
serum-starved for 24 hours before exposure for an additional 24 hours to KGF at various 
Figure 6 Expression pattern of FgfR2IIIb in the thymus. a) All MTS24+ cells are positive for 
FgfR2IIIb. Red: MTS24; green: FgfR2IIIb; yellow: colocalization. b) All UEA-1+ cells are posi-
tive for FgfR2IIIb. Red: UEA-1; green: FgfR2IIIb; yellow: colocalization. c) Only few epithelial 
cells of the medulla are positive for both CK5 and FgfR2IIIb; in addition few cortical cells also 
express both markers. Red: CK5; green: FgfR2IIIb; yellow: colocalization. d) At the CMJ minor 
cortical epithelial cells express FgfR2IIIb. Green: CK5; Blue: CK18; red: FgfR2IIIb; pink-white: 
colocalization.
a) b)
c) d)
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concentrations. Proliferation was measured by 3H-Thymidine incorporation. After 24 hours 
of KGF stimulation, the two medullary thymic epithelial cell lines demonstrated an increased 
proliferation rate, although a difference in this response was noted when comparing the two 
Figure 7 The thymic 
medullary cell line, 
TEM2.3, proliferate 
in vitro in response 
to KGF. Statistic 
analysis denote a 
significant increase 
in proliferation of 
KGF stimulated 
cells (grey bars) in 
comparison to un-
treated cells (black 
bar). Statistic: 
Anova, post-hoc-
test: Bonferroni. 
***p<0.0001
no
 K
G
F
10
 n
g/
m
l K
G
F
20
 n
g/
m
l K
G
F
40
 n
g/
m
l K
G
F
10
0 
ng
/
m
l K
G
F
50
0 
ng
/
m
l K
G
F
10
00
 n
g/
m
l K
G
F
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
TEM2.3 cell line
*** p<0.0001
3H
-I
nc
or
p
or
at
io
n 
(C
P
M
)
Figure 8 The thymic medullary 
C6 cell line, proliferate in vitro 
in response to KGF. Statistic 
analysis denote a significant 
increase in proliferation of KGF 
stimulated cells (grey bars) in 
comparison to untreated cells 
(black bar). Statistic: Anova, 
post-hoc-test: Bonferroni. 
***p<0.0001
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cell lines. TEM 2.3 cells responded best to KGF at a concentration of 100 ng/ml (Figure 7), while 
C6 cells proliferated at 20 ng/ml, but failed to do so at higher concentrations (Figure 8). The 
KGF-mediated increase in proliferation was already apparent 24 hours after stimulation. 
KGF induces ex vivo the proliferation of fetal thymic stromal cells and inhibits the reconstitution with 
thymocytes of lymphoid cell-depleted fetal lobes
To assess the biological effect of KGF on thymic epithelial cells on a more physiological ex 
vivo setting, stromal cell proliferation was measured in fetal thymic organ cultures (FTOC). To 
this end, fetal thymic lobes were removed from embryos at day 14.5 of gestation and cultured 
on a floating membrane for 6 days in the presence of 1.25 mM 2-deoxyGuanosin (2-dGuo) 
to deplete thymocytes. Following this treatment, fetal lobes were grown for two days in the 
absence of serum whereby KGF at a concentration of 100 ng/ml was added for the last 24 
hours of culture. Finally, the medium was exchanged and proliferation was measured by 3H-
Thymidine incorporation at 48, 72, and 96 hours after pulsing. For a more reliable measurement, 
individual lobes were digested 
with collagenase IV, which 
generated a single cell suspension 
of 90 % epithelial cells and 10 % 
mesenchymal cells. In keeping 
with the results observed with 
thymic epithelial cell lines, 
primary stromal cells exposed 
to KGF displayed an increased 
proliferation as early as 72 hours 
after stimulation with KGF when 
compared to unstimulated cells (Figure 9, n=8). Comparable results were also obtained from 
day 15.5 embryos thymic lobes (data not shown).
Since in vivo treatment with KGF resulted in an increased thymocyte cellularity, it was next 
determined whether treatment with KGF of 2-dGuo exposed thymic stromal cells resulted 
in a faster kinetic in lymphoid repopulation. To this end, FTOC with lobes from mice at day 
15.5 of gestation were depleted for 6 days with 2-dGuo, washed, serum-starved overnight 
and then stimulated for 48 hours with different concentrations of KGF (50, 100, and 500 ng/
ml). Subsequently, the single lobes were reconstituted overnight in Terasaki plates, using 
hematopoietic precursor cells derived from fetal liver of embryos at day 14.5 of development. 
Reconstituted lobes were then transferred to floating membranes and grown in complete medium 
(IMDM + 10% fetal calf serum) for 20 days. At the end of culture, four individual lobes were 
Figure 9 KGF induces proliferation of fetal thymic stromal cells 
in thymocytes depleted lobes from E14.5 embrios cultured ex 
vivo.
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pooled, a single cell suspension 
was generated by collagenase 
IV/DNAse and the cells 
were analyzed for cell 
surface expression using flow 
cytometry (Figure 10). A robust 
reconstitution of the lymphoid 
compartment was observed in 
lobes reconstituted cultured in 
the absence of KGF. There, the 
distribution of the thymocyte 
subpopulations (as defined 
by CD4 and CD8 expression) 
revealed an abundance of 
DP thymocytes but also the 
presence of TN and SP cells. 
The over-representation 
of TN and CD8 SP cells in 
comparison to age-corrected 
thymic tissue has already 
been seen previously (151) 
and has been explained by the 
constraints of the experimental system used. In contrast, thymic lobes pre-treated with KGF 
displayed a dramatically different pattern in lymphoid reconstitution. Here, intrathymic T cell 
development was partially blocked at the TNI stage and the progression to the maturational 
cell stages of DP and SP were in consequence severely altered in a dose-dependent manner. The 
increase of TNI cells was in direct relationship to the concentration of KGF used. In contrast, 
the suppression in the emergence of DP thymocytes was less effective in instances where 
higher KGF concentrations were used while changes in the absolute number of SP thymocytes 
was low in the presence of KGF and only mildly increased in cultures supplemented with 
the highest KGF concentrations. Taken together, these results demonstrate that KGF exerts 
a mitogenic effect on thymic stromal cells. This stimulatory effect appears to change the 
conditions for fetal support of fetal thymopoiesis in a fashion that leads to accumulation of 
the most immature intrathymic T cell precursors and a partial block in their developmental 
progression to more mature stages. 
Figure 10 The repopulation and differentiation of the lymphoid 
lineage in 2-dGuo treated thymic lobes repleted with fetal liver 
cells, is inhibited in the presence of KGF. Representative experiment, 
each bar is the average of 2 samples and each sample is the pool of 4 lobes. 
a) Separation of thymocytes subpopulation according to CD4 and 
CD8 expression. b) Separation of CD4-CD8-CD3- thymocytes into 
developmental stages TNI-IV according to CD25 and CD44 ex-
pression.
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KGF induces in vivo proliferation of thymic epithelial cells
The proliferative response of adult thymic epithelial cells was also investigated in mice treated 
for three consecutive days either with KGF or HBSS (the latter serving as a control group). 
The injected mice were also pulsed i.p. with 1 mg BrdU on the second and third day of KGF 
treatment. Ninety-six hours after initiation of treatment, mice were sacrificed and the thymus 
was removed for further analysis by flow cytometry. To this end, the tissue was enriched for 
epithelial cells with a sequence of enzymatic digestion (as detailed in the “methods” section) 
and a single-cell suspension was prepared. Thymic epithelial cells were identified as large 
cells that express MHC class II molecules but are devoid of CD45 (see Figure 11a). An increased 
number of all mature thymic epithelial subpopulations was noted when stimulated by KGF 
(Figure 11). Thus, KGF given on three consecutive days to adult mice results in an increased 
proliferation (BrdU incorporation) of all thymic epithelial cells (CD45+ MHC Class II+, Figure 
11a) and all subpopulations tested, including the rare population of MTS24+ cells, which are 
thought to serve as precursors to all cortical and medullary epithelial cells, show increased 
Figure 11 a) KGF induces the proliferation of adult thymic epithelial cells. Staining 
for TEC and BrdU incorporation in TEC compartment. b)-f) KGF increase the relative 
cell numbers for different TEC subpopulations. b) CK5. c) CK18. d)MTS10. e) UEA-1. 
f) MTS24.
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cellularity (Figure 11b-d). 
Taken together, this series of in vivo, ex vivo, and in vitro experiments could unequivocally 
demonstrate that KGF exerts a proliferative effect on fetal and adult thymic epithelial cells. This 
activity is in keeping with the expression pattern of FgfR2IIIb exclusively on thymic epithelial 
cells. In view of this biologically relevant effect on thymic epithelial cells, it is conceivable that 
KGF may be beneficial to protect or correct damages to thymic epithelial cells in the course of 
allogeneic bone marrow transplantation. 
Gene expression profiling of thymic epithelial cells stimulated with KGF
In order to begin to elucidate the genetic program activated by and accounting for the effects 
of KGF signaling, adult thymic epithelial cells exposed in vivo to KGF were analyzed for the 
expression of specific genes previously noted to play an important role in thymic epithelial 
cell development and function. For this purpose, mice were treated with a single dose of KGF 
(15 mg/Kg) or HBSS (as a control) and sacrificed 24 hours later. Epithelial cells were enriched 
after digestion of thymic tissue and sorted by flow cytometry to purity (>95 %), using MHC 
class II cell surface expression and the absence of CD45 as selection criteria. Following mRNA 
isolation and synthesis of cDNA, 
the presence of transcripts 
specific for IL-7, Wnt4, Wnt5b, 
Wnt10b, BMP2, and BMP4 was 
quantified by real-time PCR. 
As demonstrated in Figure 12, 
transcripts specific for IL-7 
were increased by 16-fold in 
consequence of KGF stimulation. 
The increase in transcripts for the 
different Wnt family members 
varied considerably: Wnt4 and 
Wnt10b were upregulated 1.5- 
to 2-fold, while Wnt5b specific transcripts were increased in response to KGF signaling by 
almost 5-fold. Moreover, a 2- and 2.5-fold increase was also observed for BMP4 and BMP2, 
respectively. Since IL-7, Wnts and BMPs have previously been implicated in intrathymic T cell 
maturation, it is not unlikely that changes in the expression of these molecules following KGF 
signaling may exert a direct influence on thymocyte development. In particular, stimulation 
via IL-7 has been reported to be important for the survival of TN thymocytes and signaling 
via Wnt-specific receptors facilitates the transition of TN cells to a DP phenotype (152). 
Figure 12 Gene expression profile of adult TEC 24 hours after 
stimulation with KGF. Value in HBSS-stimulated cells were set 
to 1 for comparison and data were normalized to the expression 
of GAPDH.
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Signaling via BMP2 and BMP4 exert an inhibitory effect and block in the progression from 
DN to DP (153, 154), particularly the progression of TNI to TNII. Thus, KGF stimulation of 
thymic epithelial cells allows for the transcriptional upregulation of several genes that affect 
intrathymic lymphoid cell development. 
To investigate in fetal thymic epithelial cells the effect of KGF signaling on gene expression 
profiles, specific transcripts were quantified in cells of FTOCs exposed either to KGF or to 
vehicle alone. To this end, thymic lobes of embryos at day 15.5 of gestation were first cultured 
in the presence of 2-dGuo for six days to deplete thymocytes and then grown for two days in 
medium containing only 1 % fetal calf serum. During the last 24 hours of culture, the medium 
was supplemented with KGF or Fgf-20 in the presence (Figure 13b) or absence (Figure 13a) 
of specific biochemical compounds inhibiting defined signaling pathways. Signaling via 
NFκB was inhibited by PS1145 (10 μM), farnesylation of Ras was prevented by the farnesyl 
transferase inhibitors L-778.123 (1 μM) and p53 function was blocked by a p53 inhibitor (all 
these substances were kindly provided by Bruce Blazar, Minneapolis). Following culture, 
cDNA was generated and analyzed by quantitative PCR for the presence of transcripts specific 
for IL-7R (IL7 receptor), FoxN1, Wnt4, Wnt5b, Wnt10b, BMP2, and BMP4. As demonstrated 
in Figure 13a, stimulation of fetal stromal cells for 24 hours with KGF resulted in a marked-up 
regulation of transcripts for IL-7R, Wnt10b, BMP2 and BMP4. In contrast, Fgf-20 signaling 
resulted only in a limited upregulation of transcripts for IL-7R, Wnt10b, and BMP2 in thymic 
stromal cells of FTOC when compared to the effect observed with exposure to KGF.
The biochemical pathways involved in KGF-mediated upregulation of IL-7R, Wnt10b, 
BMP2 and BMP4 were next investigated. Upregulation of IL-7R was not only sensitive to 
inhibition of Ras farnesylation but was partially blocked by inhibition of p53 (Figure 13b). 
Signaling to upregulate Wnt10b involved NFκB and p53 as the functional inhibition of either 
these molecules resulted in a block in KGF-mediated transcriptional activation (Figure 13b). 
Transcripts for BMP2 and BMP4 failed to be upregulated in response to KGF in the presence 
of inhibitors for Ras farnesylation and for p53 (Figure 13b). Moreover, blocking of NFκB 
inhibited also the upregulation of transcripts specific for BMP4 but not for BMP2 (Figure 13b). 
Taken together, these studies revealed, at least for fetal thymic stromal cells, that different 
intracytoplasmic signaling pathways are used for the transcriptional upregulation of distinct 
gene products. 
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Figure 13 Gene expression profile of fetal thymic stromal cells indicated as fold increase after real time 
PCR. a) Stroma cells stimulated either with KGF or Fgf20. b) Transcripts analysis after KGF stimulation 
in combination with NFkB inhibitor, Farnesyl transferase inhibitor (FTase) or p53 inhibitor.
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KGF stimulation affects indirectly also thymocyte development
In vivo KGF treatment of adult mice resulted in a robust 
increase in total thymic cellularity. As the overall 
histological structure of treated thymi remained 
unchanged and as the analysis of the stromal 
compartment revealed a proportional increase in the 
number of thymic epithelial cells, it was conceivable 
that also cells of the lymphoid compartment had an 
increase in response to KGF. To address this point 
directly, female mice C57BL/6 at 4 – 6 weeks of age 
were injected on three consecutive days with a single 
dose of KGF (5 mg/Kg/day). Thymocytes cellularity 
and phenotype were subsequently analyzed at 5, 
10, and 15 days as well as 4, 8, and 12 weeks after 
initiation of treatment. These results were compared 
to findings of HBSS injected mice investigated at identical times. As demonstrated in Figure 14, 
injection with KGF resulted in a significant increase in thymocyte cellularity when compared 
to HBSS injected controls. This change was evident as early as day 15 after treatment and 
persisted for at least 12 weeks. However, absolute cell numbers were greatly reduced on day 5 in 
both KGF and HBSS 
treated animals 
when compared to 
unmanipulated or 
HBSS injected mice 
investigated at 10 
or more days after 
the onset of the 
experiment. This 
early reduction in 
cellularity is most 
likely caused by 
stress associated 
with the handling 
and injection of 
the mice and thus 
Figure 14 KGF increases thymic cellularity. 
Mice were injected for 3 consecutive day 
with KGF (5mg/kg/day, grey bars, n=6, 
per time point) or HBSS (black bars, n=4, 
per time point) and  analyzed at the indi-
cated times. Statistic: Anova, post-hoc-test: 
Bonferroni.
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Figure 15 KGF influence TN development shortly after treatment. KGF treated 
mice: grey bars, HBSS treated mice: black bars. Statistic: Anova, post-hoc-test: 
Bonferroni.
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independent of the biological activity of the components used. Despite the lack of a difference 
between mice injected with KGF and HBSS, respectively, an ANOVA statistical analysis 
combined with a Bonferroni Post-hoch test revealed statistically significant difference in 
thymocyte cellularity at all time point analyzed, excluded day 10, between the two treatment 
groups (p<0.05 are indicated in the Figure 14). 
Next, changes in the relative frequency of thymocytes were correlated to specific developmental 
phenotypes. As demonstrated in Figure 15, a difference between the two treatment groups 
regarding the relative number of thymocytes at distinct maturational stages was only 
observed on day 5 for all TN subpopulations and on day 10 for TNIV. At all other time points, 
the measurements of the other thymocyte subpopulations failed to reveal a difference when 
comparing KGF and HBSS treated mice. These results support the conclusion that KGF 
treatment causes a proportionally correct expansion of all thymic cell lineages. 
The observed increase in cell with the different TN phenotype may have occurred as results of 
cell proliferation or, alternatively, may be the consequence of a partial maturational block at the 
transition from one to the next developmental stage. To address this issue in vivo KGF treated 
mice (5 mg/kg for 3 consecutive days) were also pulsed with BrdU (1 mg/mouse i.p) 24 hours 
before sacrifice at the time points: day 5, 10 and 15 after beginning of the treatment. Early after 
KGF stimulation (i.e. on day 5), the populations of TNI and TNII thymocytes demonstrated 
statistically significant increases in cell proliferation when compared to HBSS treated mice 
(Figure 16). Following the swift transitions through the subsequent developmental stages, 
analysis at day 10 after KGF injection revealed only for TNIV cells a difference in proliferation 
in comparison to HBSS treated mice while differences in cell cycling were not apparent 
Figure 16 BrdU incor-
poration as a mesure 
of cell proliferation of 
TN thymocytes follow-
ing in vivo exposure 
to KGF (grey bars) or 
HBSS (black bars). The 
data represent the rela-
tive percentage of thy-
mocytes with a specific 
phenotype that have 
incorporated BrdU. Sta-
tistic: Anova, post-hoc-
test: Bonferroni.
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anymore on day 15 after the initiation of the treatment.
The observed relative changes in cell proliferation after injection has to be interpreted in relation 
to thymic cellularity at the different time points. The absolute cell number for thymocytes 
and the relative percentage of DP cells is decreased on day 5 following the injections when 
compared to unmanipulated mice (Figure 17). Interestingly, the relative number of DN cells was 
also increased on day 5 after KGF treatment, when compared to later time points. This increase 
occurs parallel to stress-related changes and may thus reflect a physiological mechanism of 
corrective repopulation, possibly initiated by an increased thymopoiesis triggered through the 
expansion of TNI cells (Figure 16). Changes in the relative number of thymocytes of a given 
SP phenotype was only observed at day 5 after KGF treatment when the number of DP cells 
decreased in comparison to control mice. An obvious explanation for this finding is presently 
Figure 17 Maturing 
thymocytes sub-
populations analysis 
in response to KGF 
stimulation. KGF treat-
ment: grey bars; HBSS 
treatment: black bars. 
Statistic: Anova, post-
hoc-test: Bonferroni.
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Figure 18 BrdU incorpora-
tion analysis of maturing 
thymocytes. KGF treat-
ment reduce for short term 
the proliferative capacity 
of DPs. KGF treated mice: 
grey bars, HBSS treated 
mice: black bars. Statistic: 
Anova, post-hoc-test: Bon-
ferroni.
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lacking. However, the absolute thymocyte cell number was 
comparable between the two treatment groups at day 10 and 
increased significantly thereafter for the KGF injected animals 
(Figure 14). These dynamic changes were also reflected in the 
analysis of the thymocytes subpopulations actively cycling. 
For this purpose, mice treated with either KGF or HBSS were 
pulsed i.p. with BrdU and analyzed 24 hours later by flow 
cytometry for the incorporation of this modified uridine 
base. As demonstrated in Figure 18 a difference in the BrdU 
incorporation between the two treatment groups was only 
observed on day 5 for DP thymocytes. This finding suggest 
that thymocyte development occurs normally in KGF treated mice relative to HBSS injected 
mice but at a steady-state level involving higher total cell numbers.
To determine whether thymic selection is altered following treatment with KGF, Vβ chain 
usage for the T cell antigen receptor was analyzed by flow cytometry (Figure 19). To this 
end, (C57BL/6 x DBA/2) F1 mice were treated with KGF (5 mg/kg) on 6 consecutive days 
and analyzed 15 days later. The usage and cell surface density of the Vβ expression was 
comparable between the KGF and HBSS treated groups of mice, thus excluding the possibility 
that thymic selection in a microenvironment exposed in vivo to KGF would alter thymic 
selection. However, only further molecular and functional analysis will unequivocally answer 
the question whether KGF treatment will result in a skewing of the antigen receptor repertoire 
of treated mice beyond the use of specific Vβ families.
Detection of early thymic emigrants
The increase of thymic cellularity represents a striking finding in KGF treated mice and is 
clearly coincident with the proliferation of thymic epithelial cells. However, mechanisms 
independent of a cellular expansion of thymic stroma could contribute to increased thymocyte 
numbers. For example an identical increase in cellularity may also be achieved secondary to 
a higher percentage of cells undergoing proliferation or, alternatively, following a dramatic 
decrease in the exit of mature thymocytes to the periphery. However, both of these explanations 
have been excluded as possible mechanisms operational in KGF treated mice. Differences in 
cell proliferation were not observed day 10 following KGF treatment, but a difference in total 
cellularity between the two treatment groups persisted for at least 12 weeks. A block in the 
exit of mature thymocytes to the periphery is also unlikely explanation since the relative 
distribution of the distinct thymocyte subpopulations remained largely normal over the course 
of 12 weeks and specifically a disproportionate accumulation of single positive thymocytes 
Figure 19 KGF do not influence 
the Vβ repertoire of thymocytes. 
KGF treatment: grey bars; HBSS 
treatment: black bars.
Vβ7 Vβ8.2 Vβ10 Vβ12 Vβ14
0
%
 o
f 
C
D
3h
iV
β+
/
C
D
3h
i
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
52 53
could not be observed. Because a regular distribution of thymocytes subpopulations had 
been noted following in vivo KGF stimulation, thymopoiesis occurs normally albeit at higher 
steady-state level when compared to HBSS treated mice.
It is nevertheless still conceivable that thymocyte export and survival in the periphery may 
be altered in KGF treated mice. To address directly this issue, thymocytes were labeled in vivo 
and their exit as mature T cells was monitored in lymph nodes and spleen. For this purpose, 
anesthetized naive female C57BL/6 mice (4 weeks of age at the moment of KGF/HBSS 
treatment) previously treated with either KGF (5 mg/kg on three consecutive days) or HBSS 
were intrathymically injected with FITC (10 μl of a solution containing 125 μg/ml of FITC 
Figure 20 Cellularity of a) the thymus, b) spleen and c) lymphnodes in presence or absence of KGF 
treatment (day 0, 1, 2) and 16 hours after intrathymic injection of FITC. Black bars: saline control (day 
8, n=15; day 45, n=10). Grey bars: KGF treated (day 8, n=14; day 45, n=17). Statitsical analysis: Mann-
Whitney U.
0
20
40
60
80
100
120
140
0
20
40
60
80
100
120
140
160
180
200
HBSS KGF HBSS KGF
0
20
40
60
80
100
120
140
HBSS KGF
0
10
20
30
40
60
70
80
HBSS KGF
90
0
HBSS KGF
5
10
15
20
25
30
0
HBSS KGF
10
20
30
40
50
a) Thymus
b) Spleen
c) Lymphnodes
To
ta
l c
el
l n
u
m
be
r 
x1
0*
6
day 8 day 45
p<0.0001
p=0.0005
p=0.012
52 53
HBSS KGF HBSS KGF
0
0.03
0.05
0.08
0.1
0.12
0.15
0.17
0.2
0.23
CD4+ CD8+
HBSS KGF HBSS KGF
CD4+ CD8+
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
HBSS KGF HBSS KGF
0
0.03
0.05
0.08
0.1
0.12
0.15
0.17
0.2
0.23
CD4+ CD8+
HBSS KGF HBSS KGF
0
0.02
0.04
0.06
0.8
0.1
0.12
0.14
0.16
0.18
CD4+ CD8+
Spleen: % of tot cells number
Spleen: total cells number x10*6
day 8 day 45
p<0.0001 p=0.0010
p=0.0011 p=0.0232
p=0.0019
p=0.0013p=0.0209
a)
b)
Ln: % of tot cells number
HBSS KGF HBSS KGF
CD4+ CD8+
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
HBSS KGF HBSS KGF
CD4+ CD8+
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4 0.4
Ln: total cells number x10*6
HBSS KGF HBSS KGF
0
0.02
0.04
0.06
0.8
0.1
0.12
CD4+ CD8+
HBSS KGF HBSS KGF
0
0.02
0.04
0.06
0.8
0.1
CD4+ CD8+
p<0.0001 p=0.0219
p=0.0052
Figure 21 KGF treatment increases long term early thymic emigrants rate. a) spleen and b) lymphnodes in pres-
ence or absence of KGF treatment (day 0, 1, 2) and 16 hours after intrathymic injection of FITC. Black bars: sa-
line control (day 8, n=15; day 45, n=10). Grey bars: KGF treated (day 8, n=14; day 45, n=17). Statitsical analysis: 
Mann-Whitney U.
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in PBS) in a single lobe on day 8 and day 45 post KGF/HBSS treatment. These particularly 
time points were chosen as at day 8 the total thymocytes cellularity is identical between the 
two treatment groups and at day 45 the thymic cellularity is double in the KGF mice since 20 
days and the output has reached a steady-state condition. Mice were sacrificed 16 hours after 
intrathymic injection and thymus, spleen and lymph nodes were removed for the detection by 
flow cytometry of CD4 and CD8 FITC positive T cells. As shown in Figure 20 thymic cellularity 
is the same at day 8 for both groups and is doubled at day 45 for the KGF treated group. In the 
spleen and in the lymph nodes the read out is opposite: at day 45 no difference is detectable 
between the two treatment groups. As demonstrated in Figure 21, the relative and absolute 
numbers of FITC positive CD4 cells was decreased in both spleen and lymph nodes at day 8 
after KGF treatment if compared to the HBSS treated group. In contrast, the relative but not 
the absolute number of CD8 FITC positive cells in the lymph nodes of KGF treated animals 
were decreased at day 8 after treatment, however in the spleen the relative and the absolute 
cell numbers resulted decreased in this group. While this finding may be indicative of a KGF 
induced reduction in thymic export, obvious limitations inherent to this assay allow also other 
interpretations. For example, it is conceivable that thymic exit is unaffected by KGF treatment 
but that the distribution and/or survival of newly generated T cells is altered secondary to 
this treatment. Moreover, either or both of these alternative explanations could hold true 
for the entire time period during which KGF effect can be noted or, alternatively, once KGF 
mediated thymic expansion has reached a plateau, mature single positive thymocytes may 
exit undisturbed. To address this later point, FITC labeling was performed 45 days after KGF/
HBSS treatment. At this time point the output to the spleen of labeled thymocytes within 16 
hours was increased when compared to HBSS treated mice. This change affected both CD4+ 
and CD8+ T cells. However, the identical analysis of recent thymic emigrants homing to lymph 
nodes failed to document such a difference. These data demonstrate that the thymic output is 
increased in mice treated with KGF once size has increased and a steady state in thymopoiesis 
has been reached. 
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The role of KGF in GVHD associated pathology to the thymus
Thymic stroma cells constitute a typical target of GVHD mediated tissue destruction by donor 
derived alloantigen specific T cells. This pathology appears to limit the capacity of recipients 
of an allogeneic hematopoietic stem cell transplantation (HSCT) to rapidly and completely 
reconstitute the peripheral T cell compartment. Any preventive or therapeutic measures aimed 
at the structural and functional maintenance of thymic epithelial cells has, therefore, been 
tought to be of great benefit to the outcome of HSCT. Thus, the provision of KGF was assessed 
for its capacity to act as a cytoprotective or cytoreparative agent in a clinically relevant model 
of GVHD mediated injury to the thymus. 
Treatment of transplant recipients with KGF diminishes thymic GVHD
To investigate the role of KGF in the prevention and repair of thymic GVHD, a murine 
haploidentical transplantation model was used that is independent of total body irradiation 
or other cytotoxic pre-conditioning regimens that may adversely affect thymocytes and 
thymic epithelial cells. Severe acute GVHD was elicited in B6D2F1 mice by transfer of 25 x 
106 unseparated splenocytes from C57BL/6 donors. In addition, the transplanted mice (B6 
-> B6D2F1) were treated subcutaneously from day –3 to day +3 of transplantation with either 
HBSS or KGF (5 mg/kg/day). HBSS treated B6D2F1 recipients of 25 x10
6 syngeneic B6D2F1 
splenocytes served as controls.
The effect of KGF on thymic weight, cellularity and function was investigated on day 13 
after transplantation. As demonstrated in Figure 22a and b, allogeneically transplanted mice 
injected with HBSS suffered a significant loss in thymic weight and cellularity when compared 
to syngeneic controls. However, treatment with KGF fully inhibited this GVHD-induced 
thymic injury. Thymocytes of syngeneically transplanted mice treated with KGF displayed 
normal thymocyte maturation comparable to B6D2F1 -> B6D2F1 mice treated with HBSS. 
Notwithstanding, thymic weights were increased by approximately 50%.
As the extent of thymic damage had been previously correlated with the presence of mature 
donor T cells entering the thymus (142), we next determined the frequencies and absolute 
numbers of infiltrating T cells of donor origin in these mice. Thymic single cell suspensions 
of Ly5.2+ recipients were analyzed by flow cytometry for the in situ presence of mature Ly5.1+ 
cells. KGF-treatment diminished the relative percentage of thymus-infiltrating T-cells, and 
in particular that of mature CD8+ cells, when compared to HBSS-treated mice (Figure 22c). 
However, the absolute number of donor-derived T-cells was several-fold higher in KGF-
treated hosts when compared to control transplant recipients (i.e. injected with HBSS). Thus, 
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the protective effect of KGF on thymocyte development in presence of GVHD was not due to 
a decrease in thymus-infiltrating mature T cells.
Thymocytes of syngeneically and allogeneically transplanted recipients treated with either 
HBSS or KGF were further analyzed for expression of CD3, CD4 and CD8. Comparing the 
three experimental groups, significant changes in the relative number of TN thymocytes were 
not observed (Figure 22d). However, the DP population was severely diminished while single-
positive mature thymocytes were greatly increased in B6 -> B6D2F1 recipients treated with 
HBSS. These changes were typical for GVHD-mediated thymic pathology and are accounted 
by both enhanced apoptosis of DP thymocytes and the presence of mature donor T-cells in 
the thymus (142). In contrast, mice injected with allogeneic T cells and KGF displayed normal 
thymocyte maturation with the notable exception of an increased number of CD3+ T cells, 
likely reflecting the presence of mature T cells of donor origin. Taken together, these results 
demonstrated that treatment with KGF prevented the GVHD-associated thymic changes in 
weight, cellularity and cell maturation, independently of effects on the thymic recruitment of 
donor-derived T cells.
KGF treatment maintains normal cell cycle progression of resident TCR-CD4-CD8- thymocytes despite 
acute GVHD
Two weeks after transplantation, the absolute cellularities within each of the four phenotypically 
distinct TN thymocyte subpopulations were significantly decreased in mice injected with 
saline (Figure 23, upper panel). In contrast, treatment with KGF preserved cell numbers for each 
of the TN subpopulations. Thus, KGF prevented the loss of the most immature pro-T and pre-
Figure 22  Treatment of mice with KGF diminishes thymic GVHD. Acute GVHD was induced by transfer 
of 25 x 106 parental B6 splenocytes to unirradiated B6D2F1 mice. Recipients were analyzed on day 13 
after transplantation. Mice were treated from days -3 to +3 of transplantation with KGF (i.p., 5.0 mg/
kg/mouse/day KGF)      or HBSS      . B6D2F1 mice transplanted with syngeneic splenocytes served as 
non-GVHD controls and did receive neither KGF nor HBSS      . Panels a.) and b.): thymus weight (mg) 
and cellularity (total cell number x 10-6) were determined. Panel c.): infiltration of donor T cells into the 
thymus (in percent, left, and total cell number x 10-5, right). Donor-derived T cells were distinguished 
from host cells (CD45.2+) by the expression of CD45.1. Panel d.): cell surface expression of CD3, CD4 and 
CD8 on thymic cells was analyzed by flow cytometry and the major thymocyte subsets were quantified 
(% of total cells, panel below). TN, CD3,4,8-triple negative; DP, CD4,8 double-positive. The graph repre-
sents pooled data from three independent experiments; with 10 mice analyzed for each group. Analysis 
by ANOVA; *p<0.05.
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Figure 23 KGF treatment maintains normal cell cycle progression of the most immature thymocyte 
subsets. Acute GvHD was induced in unirradiated B6D2F1 mice as in Figure 22. CD3,4,8-triple negative 
(TN) thymocytes were analyzed 13 days after transplantation for surface expression of CD44 and CD25 
and for BrdU incorporation. Upper panels: TN cellularity (total TN cell number x 10-5) in mice treated 
with KGF      or with HBSS      was ascertained and compared to untreated syngeneically transplanted 
B6D2F1 mice     . Lower panels: the absolute cell numbers (x 10
-4) of BrdU+ cells among TN thymocytes 
were determined. Each graph represents pooled data from two independent experiments, with 7 mice 
analyzed for each group. Analysis by ANOVA; *p<0.05.
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T cells in the presence of alloreactive T cells.
As the loss of TN cells during GVHD is the consequence of impaired cellular proliferation, we 
investigated whether KGF averted this functional deficiency. BrdU incorporation was used 
to determine cell cycle progression (155), which normally occurs at all phenotypic TN stages 
and in particular within stages II and IV. In B6 -> B6D2F1 recipients injected with HBSS, viable 
Figure 24 KGF treatment does not affect the severity of splenic GVHD. Acute GVHD was induced in 
unirradiated B6D2F1 mice as in Figure 22 and recipients were analyzed on day 13 after transplantation. 
Panels a.) and b.): spleen weights (mg) and cellularities (cells x 10-6)  in transplant recipients treated with 
KGF      or HBSS    . Untreated syngeneically transplanted B6D2F1 mice served as non-GVHD controls    . 
Panel c.): infiltration of donor T cells into the spleen (in percent, left panel, and total cell number x 10-6, 
right panel) was determined. Donor-derived T cells were distinguished from host cells (CD45.2+) by their 
expression of CD45.1. Panel d.): the surface expression of CD4 and CD8 on splenocytes was analyzed 
by flow cytometry and quantified (% of total splenocytes). The graphs represent pooled data from three 
independent experiments; with 10 mice analyzed for each group. Analysis by ANOVA; *p<0.05.
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Figure 25 KGF treatment preserves the thymic microenvironment during acute GVHD. GVHD was 
induced in KGF- or HBSS-treated B6D2F1 mice, as described in Figure 22 and mice were analyzed on day 
13 after transplantation. Panel a.): frozen thymic sections (6 µm) from the three transplant groups were 
analyzed for histopathology (H+E stain; magnification x 200). Panel b): immunohistology of four distinct 
subpopulations of thymic epithelial cells in allogeneically and syngeneically transplanted mice. Thymic 
epithelial cells were identified using a panel of antibodies according to Table 1. Two- and three-color 
immunoflourescent analyses, respectively, were performed using a confocal microscope (Carl-Zeiss). 
Major cortical cells appear blue (a-c), whereas minor cortical TEC (d-f), major medullary TEC (g-i) and 
minor medullary TEC (j-l) appear white (i.e. the combination of blue and red fluorescence, altered by 
computer assisted management, see Table 1). The arrows denote individual positive cells. Magnification 
x 200. The data substantiate that KGF treatment preserves in the presence of GvHD the normal structure 
of cortical and major medullary TECs but not of the subpopulation of minor medullary TECs.
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TN cells of stages II, III and IV were severely affected by GVHD in their proliferative capacity 
(Figure 23, lower panel). However, in KGF treated mice with GVHD, the TN subpopulations 
II and III proliferated at normal (TNIII) or even increased (TNII) levels. For TNIV cells, the 
GVHD-induced inhibition of cell cycle progression was only partially reversed by KGF.
KGF treatment fails to modulate splenic GVHD
Since the spleen serves as a typical target of acute GVHD, we next assessed the extent of splenic 
damage in B6 -> B6D2F1 mice treated either with KGF or HBSS. KGF influenced neither weights 
nor absolute splenic cellularities in allogeneically transplanted recipients when compared to 
mice injected with HBSS (Figure 24a and b). Moreover, treatment with KGF had no effect on 
the degree of donor T-cell infiltration (Figure 24c). Phenotypic analysis by flow cytometry of 
splenocytes revealed for both groups of recipients a loss in non-T cells (e.g. B lymphocytes) in 
lieu of CD4+CD8- and CD4-CD8+ T cells (Figure 24d). Thus, in vivo administration of KGF did 
not affect the severity of splenic GVHD.
KGF treatment essentially preserves the thymic microenvironment despite GVHD
The loss of normal thymic morphology is a typical feature of GVHD and has recently been 
linked to the alloimmune response directed against thymic stromal components. Since 
normal T-cell development was preserved by KGF despite acute GVHD (as judged by splenic 
alterations) and since KGF receptor expression was detected exclusively on thymic epithelial 
cells in all anatomical compartments of the thymus, the cellular stromal composition and 
architecture of the thymic microenvironment was investigated in B6 -> B6D2F1 recipients. 
Figure 25a shows that the clear separation between cortex and medulla was lost in acute GVHD 
in mice treated with HBSS but was clearly maintained in recipients injected with KGF. As 
already detailed in the first section of this work immunohistology using UAE-1 lectin, MTS-
10 and antibodies to cytokeratin (CK) 5 and CK18 distinguished thymic epithelial cells into 
four distinct subpopulations: the major cortical (CK18+CK5-UEA-1-MTS10-), the minor cortical 
(CK18+CK5+), the major medullary (CK5+MTS10+) and the minor medullary epithelial cells 
(CK18+UEA-1+) (28)(see Table 1). In HBSS treated B6 -> B6D2F1 mice the major cortical epithelial 
cells were severely diminished in cell number in response to acute GVHD, thus contributing to 
a smaller cortex (Figure 25b, panel b). In contrast, treatment with KGF preserved the cellularity of 
this subpopulation to a degree indistinguishable to that of syngeneic transplantation controls 
(Figure 25b, panels a and c). The frequencies of minor cortical and major medullary epithelial 
cells also remained unchanged in mice injected with KGF when compared to syngeneic 
transplantation controls, whereas recipients injected with HBSS sustained a substantial loss 
of both of these subpopulations (Figure 25b, panels d-i). Only minor medullary epithelial cells 
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appeared to be unaffected by KGF treatment because both treatment groups of B6 -> B6D2F1 
recipients were shown to display an almost complete loss of this subpopulation (panels j-l). 
However, this subpopulation of epithelial cells did express the KGFR in naive thymi.
KGF affects thymic epithelial cell function
The effect of KGF on thymic epithelial cells may include alterations in gene expression that 
result in enhanced biological functions, thus maintaining normal thymocyte maturation 
despite the presence of allogeneic T cells. In normal thymic development, epithelial cells 
produce necessary chemotactic and activating stimuli to lymphoid precursors, (e.g. thymic 
epithelial chemokine; TECK (156) and macrophage inflammatory protein-1; Mip-1 (157)). 
Moreover, these cells provide crucial survival and proliferation signals for TN cells, (e.g. 
IL-7) (158), and unique molecules necessary for repertoire selection of DP thymocytes (e.g. 
autoimmune regulator; Aire) (159-161). To investigate whether KGF influence the expression 
of these molecules during acute GVHD, quantitative RT-PCR analysis was performed on 
thymic tissues. Thymic epithelial cell specific transcripts were normalized to the expression of 
the epithelial V-like antigen, EVA (157). Expression of the chemokine TECK was significantly 
diminished in epithelial cells during GVHD but was partially restored by KGF treatment 
(Figure 26a). In contrast, IL-7 expression was increased among thymic epithelial cells during 
GVHD albeit not statistically significant. KGF treatment had no further effect. Analysis for 
the expression of the transcription factor Aire, which is usually expressed in minor medullary 
Figure 26 KGF modulates 
gene expression in thymi 
from transplanted mice. 
Acute GvHD was induced 
in unirradiated B6D2F1 mice, 
as described in Figure 22. 
Recipients of allogeneic T cells 
were treated with either 
KGF      or HBSS     . 
Syngeneically transplanted 
mice served as non-GVHD 
controls     . RNA  isolated 
from whole thymic tissue 
was analyzed 13 days after 
transplantation by quantitative 
RT-PCR for transcripts specific 
for IL-7, TECK and Aire (panel 
a.) and for Mip-1α, Mip-1β 
and granzyme B (panel b.), 
respectively. TEC-derived 
transcripts (TECK, IL-7, Aire) 
were normalized for EVA expression whereas hematopoietic cell-specific transcripts (granzyme B, 
Mip-1a and b) were normalized for GAPDH expression. Each graph represents pooled data from one 
experiment; with three mice analyzed for each group. Analysis by ANOVA; *p<0.05.
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epithelial cells (160), revealed a decrease of specific mRNA following GVHD. KGF treatment 
did not restore Aire expression, which is in agreement with a lack of minor medullary epithelial 
cells in KGF-treated mice with GVHD (Figure 26a).
Since infiltrating T cells mediate a strong inflammatory response possibly affecting thymic 
epithelial cell, in the non-irradiation model of GVHD used here, was investigated whether 
KGF altered the thymic microenvironment and resulted in decreased inflammation. The 
mRNA species for granzyme B, Mip-1α and Mip-1β were therefore measured by quantitative 
PCR and normalized to GAPDH expression. Transcripts for granzyme B, a cellular activation 
marker of cytotoxic T cells, were greatly increased in thymic tissue affected by GVHD (Figure 
26b). Treatment with KGF reduced the number of granzyme B-specific transcripts by two-fold, 
despite the fact that the absolute number of donor T cells was increased in these mice when 
compared to saline treated animals with GVHD. The expression of macrophage inflammatory 
proteins-1a and 1b, i.e. important mediators of inflammation (162) was upregulated during 
acute thymic GVHD (Figure 26b). Treatment with KGF reduced specific transcripts of these 
chemokines by 3- to 4-fold; despite the increased number of infiltrating donor T cells in the 
thymus.
KGF reduces CD80 expression in thymic GVHD
CD80 (B7.1) is a critical co-stimulatory 
molecule for thymocyte development 
and mature T cell function (163, 164). 
Therefore the CD80 expression in 
thymic tissue sections of syngeneically 
and allogeneically transplanted mice 
was determined. The comparison of the 
staining revealed a pattern compatible 
with CD80 expression on thymic 
epithelial cells (data not shown)). 
We found that CD80 expression was 
upregulated in the thymus in the 
presence of acute GVHD (Figure 27). 
Treatment with KGF diminished this 
expression in both the cortical and 
medullary compartment to a degree 
comparable of syngeneic transplant 
recipients despite an increase in the 
a.)
b.)
Fo
ld
 in
cr
ea
se
2
1.5
1
0.5
0
CD80
B6D2F
1
 -> B6D2F
1
B6 -> B6D2F
1
B6 -> B6D2F
1
,
KGF
Figure 27 KGF reduces CD80 
expression on thymic stromal 
cells in recipients with GVHD. 
Acute GVHD was induced in 
KGF-treated or HBSS-treated 
B6D2F1 mice, as described in 
Figure 22. Panel a.) Thirteen 
days after transplantation, 
frozen thymic sections (6 µm) 
from the three transplant 
groups were stained with anti-
CD80 moAb and developed with AEC. Slides were then 
counterstained with hemalaun. Magnification x 200. 
Panel b.)RNA  isolated from whole thymic tissue was 
analyzed 13 days after transplantation by end-point RT-
PCR for transcripts specific for CD80. Transcripts were 
normalized for EVA expression. The graph represents 
pooled data from one experiment; with three mice 
analyzed for each group. Analysis by ANOVA; *p<0.05.
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absolute number of mature donor-derived T cells. These immunohistologic findings (Figure 
27a) were further corroborated by quantitative PCR analysis (Figure 27b). Thus KGF treatment 
reduces the cell surface expression of the costimulatory molecule CD80 on stromal cells (and 
possibly other cells, including activated T cells) and may thus hamper their allogeneicity.
Donor T cell activation in thymic tissue exposed to KGF
Thymic epithelial cells are typically targeted by donor T cells in the course of GVHD; changes 
in the architecture and composition of these stromal cells become apparent between day 
9 and 13 after donor T cells transfer. While the thymocyte cellularity remained normal in 
recipients treated with KGF when compared to animals injected with HBSS, mice of both 
treatment groups displayed first a decrease and by day 13 a complete loss in the population 
of minor medullary epithelial cells as a consequence of GVHD (Figure 25b). The understand of 
this feature  detailed studied between day 9 and 11 were carried out(Figure 28): donor T cells 
infiltration was studied on histological sections and in Figure 28b it is clear that the infiltrating 
donor T cells preferentially circulate near to the minor medullary epithelial cell subpopulation. 
Although the complete loss of this population at day 13, likely to be directly mediated by 
allogeneic T cells; histological attempts, to detail the precise molecular mechanisms by which 
these particular epithelial cells are destroyed, remained unsuccessful (data not shown). For 
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Figure 28 Donor lymphoid cells infiltrating the thymus are mostly located in the 
medullary compartment. GVHD was induced as described in Figure 22. Analysis was 
performed at day 9 post transplantation. a.) Immunohistological staining for CD45.1+ 
cells in the thymus (in red). Donor lymphoid cells are located mostly in the medulla. 
b.) Fluorescent detection for UEA-1 lectin (minor medullary TEC) in red and CD45.1+ 
cells in green.
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Figure 29 Early thymic infiltration of T cells is not modulated by KGF.  GVHD and KGF treatment were 
performed as described in Figure 22. a.) Total thymic cellularity at d9, d10 and d11 after transplantation. 
b.) Relative cells number of donor T cell in the thymus. c.) Relative cell numbers of activated CD69+ 
among donor T cells. d.) Relative cell numbers of activated CD69+ among all thymocytes. F1->F1: n=1 
per time point; B6 ->F1 -/+ KGF: n=3 per time point
66 67
example, all attempts to stain tissue section for the presence of the activated form of caspase-
3 using phospho-specific antibodies could not confirm perforin-mediated apoptosis in this 
specific thymic epithelial cell subpopulation.
To further elucidate the pathomechanisms operating in this loss of minor medullary epithelial 
cells, thymus-infiltrating donor T cells were analyzed for their anatomical location and state 
of activation in the recipient. On day 9 after transfer, these cells had accumulates in the 
thymic medulla (Figure 28a). In the further course of the disease (Figure 29), thymic cellularity 
decreased over the next 2 days progressively in the allogeneic HBSS treated mice. In contrast, 
recipients injected with KGF did not display a change in total thymocytes number (Figure 29a). 
Moreover, these changes correlated with the relative number of donor T cells infiltrating the 
thymus (Figure 29b). Although the relative percentage of an activated phenotype (i.e. CD69+) 
among the thymic infiltrating donor T cells detected in the thymus of KGF treated mice was 
higher than in the HBSS treated group (Figure 29c), these cells represent only a small minority 
among all thymic cells in this treatment group (Figure 29d). Thus, KGF does not prevent in 
absolute terms the influx of donor T cells into the thymus and does not alter their activation 
when compared to mice pretreated with HBSS and injected with allogeneic T cells.
KGF increase long-term survival of mice with acute GVHD
To determine the effect of KGF on survival following the transfer of allogeneic T cells, mice 
were treated with either KGF (5 mg/kg/day) or HBSS for 6 consecutive days and transplanted 
on the third day with 25 x 106 splenocytes. KGF treatment resulted in the long-term survival of 
the 80% of the transplanted mice. In contrast, all mice that had received HBSS did succumb to 
GVHD (Figure 30a). 
Moreover, there 
were no differences 
in total body weight 
m e a s u r e m e n t 
during the 
observation period 
of 49 days when 
comparing KGF 
treated mice 
receiving allogeneic 
T cells with mice 
engrafted with 
Figure 30 KGF treatment improves the survival and body weight of mice 
transfused with allogeneic T cells. Mice were transplanted and treated as de-
scribed in Figure 22. a) Survival curve (n=6 per group). b) Weight curve (n=6 
per group). F1 ->F1, HBSS: ; F1 ->F1, KGF: ; B6 ->F1, HBSS:    ; B6->F1, 
KGF:    .
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Figure 31 Addition of KGF 3 weeks after T cell engraftment does not alter the clini-
cal course. Mice were ransplanted and treated as described in Figure 22. a) Survival 
curve . b) Weight curve (n=6 per group). F1 ->F1, HBSS:    (n=6 per group); F1 ->F1, 
KGF: (n=6 per group); B6 ->F1, HBSS:    (n=6 per group); B6->F1, KGF: (n=12 per 
group).
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syngeneic T cells (Figure 30b). Neither survival nor changes in body weight were affected 
when additional doses of KGF were provided to engrafted mice on day 21, 22 and 23 after 
transplantation (Figure 31). Thus, the additional treatment of transplanted mice with KGF 
three weeks after the transfer of allogeneic T cells did not convey a beneficial effect even when 
animals were observed for a total of 12 weeks.
To asses the thymic damage in mice 4 weeks after infusion of allogeneic splenocytes (25 x 106), 
thymic cellularity was determined in the KGF and HBSS treated groups. As demonstrated 
in Figure 32a, thymic cellularity was increased in KGF treated mice when compared to the 
respective control group. The different values for cellularity and phenotype of maturing 
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Figure 33 Analysis of the thymus at week 12 post transplantation. a) Thymic cellularity. b) Thymic 
phenotype according to DN, DP, CD4 SP and CD8 SP. c) Donor derived T cells resident in the thymus; 
CD3+CD69+ active donor T cell, CD4 SP and CD8 SP. Groups: F1->F1, HBSS, n=3;  B6->F1, KGF, n=6.
a)
Figure 32 Analysis of the thymus at week 4 post transplantation. a) Thymic cellularity. b) Thymic pheno-
type according to DN, DP, CD4 SP and CD8 SP. c) Donor derived T cells resident in the thymus; CD4 SP 
and CD8 SP. Groups: F1->F1, HBSS, n=3; B6->F1, HBSS, n=2; B6->F1, KGF, n=3.
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thymocytes (Figure 32b) were, however, distributed over a large range reflecting a variable 
response to KGF. Moreover, donor derived T cells could still be detected in thymic tissue at 
low frequency despite normal to increased thymocytes numbers demonstrated in Figure 32c. 
The comparative analysis at 12 weeks after transplantation revealed two separate groups of 
recipient mice in the allogeneic transplanted and KGF treated group as discriminated by total 
thymic cellularity (Figure 33a). Almost all the mice treated with KGF had a regular distribution 
of the DP thymocytes but shows an increased relative cell number of SP thymocytes (Figure 
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Figure 34 Analysis of the spleen at week 12 post transplantation. a) Spleen cellularity. b) Spleen phenotype 
according to CD3- CD4 SP and -CD8 SP. c) Donor derived T cells resident in the thymus; CD3+CD69+ 
active donor T cell, CD3- CD4 SP and -CD8 SP. Groups: F1->F1, HBSS, n=3;  B6->F1, KGF, n=6.
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33b). Analysis of donor T cells present in the thymus of these mice revealed heterogeneous 
values for CD4 SP and CD8 SP  (Figure 33c) and high values, but heterogeneous, for the early 
activation marker CD69.
The analysis of the spleen at 12 weeks after transplantation demonstrated similar findings 
(Figure 34). With the notable exception of two mice, the total cellularity was decreased in 
all recipients of allogeneic transplanted and KGF treated mice (Figure 34a). This loss was 
paralleled by a persistence of donor T cells whereby a higher number of these alloreactive cells 
corresponded also to an increased frequency of activated donor T cells (Figure 34c). The host T 
cells consisted of CD4 and CD8 subpopulation at an almost normal ratio (Figure 34b).
The persistence of donor T cells for at least 12 weeks after engraftment and the decrease in 
total thymic and splenic cellularity in some of the transplanted mice rescued with KGF are 
reminiscent of chronic GVHD. This disorder is highlighted by the production of antibodies 
against nuclear components and single-strand (ss) DNA. To asses whether the prolonged 
survival of these KGF treated recipients of allogeneic splenocytes resulted in a state of chronic 
GVHD, the sera of mice were tested for the presence of auto antibodies. For this purpose, 
kidney and liver tissue sections from Rag-/- mice were incubated with serum collected 12 
weeks post transplantation from syngeneically transplanted mice, HBSS treated or allogeneic 
transplanted mice treated with KGF. As demonstrated in Figure 35 serum derived the latter 
group of mice contained anti-nuclear auto-antibodies, while serum from the control group 
Figure 35  Anti nuclear auto-antibodies are present in the serum of allogeneic transplanted 
mice treated with KGF.
Serum from F1->F1, HBSS, week12 Serum from B6->F1, KGF, week12
Kidney
Liver
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was deprived of auto-antibodies. Taken together, the extended survival secondary to KGF 
treatment appears to be paralleled with the detection of anti-nuclear antibodies, a characteristic 
feature of chronic GVHD.
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Discussion
The thymus is the primary lymphoid organ for the generation and selection of T cells (1, 2). 
The loss of thymic function, either as a consequence of physiological senescence or the result 
of disease- and/or treatment-related pathology, affects the individual’s capacity to maintain a 
broad T cell antigen receptor repertoire (165). In consequence, the ability to mount an efficient 
adaptive immune response may become restricted. Novel cell therapeutic and pharmacological 
strategies that have been designed to maintain regular thymic function despite the presence 
of adverse influences (e.g. radiation, chemotherapy, or GVHD) have, therefore, attracted an 
increased interest for their clinical application (166, 167). In this context, the therapeutic use 
of KGF holds a significant potential and great promise. The work presented here reports on 
the preclinical results supporting the use of KGF in the treatment of immune suppression 
following hematopoietic stem cell transplantation.
In vivo treatment of naive mice with a short course of pharmacological doses of KGF results in a 
2- to 3-fold increase in thymocyte cellularity as early as two weeks after initiation of treatment. 
This effect lasts for at least 12 weeks and affects both lymphoid and epithelial cells. As the specific 
receptor for KGF, FgfR2IIIb is exclusively restricted in its expression to the thymic epithelial 
cells, changes in the number of thymocytes have to occur through an indirect mechanism, i.e. 
through the physiological mechanisms of lympho-stromal cross-talk. It is perceived as likely 
that the increase in thymic epithelial cells provides a larger number of micro-environmental 
niches that are able to support thymopoiesis. Independent of this contention, it is striking that 
not all thymic epithelial cells express FgfR2IIIb when analyzed by immunohistochemistry. 
While the putative precursor population of MTS24+ thymic epithelial cells and the UEA-1+ 
minor medullary epithelial cells stain uniformly positive for FgfR2IIIb, only few of the major 
cortical and major medullary epithelial cells stain positive for this specific receptor. Despite this 
restricted FgfR2IIIb expression pattern, KGF treatment results interestingly in a proportionally 
correct expansion of the thymic epithelial compartment. This may either be brought about by 
the expansion and maturation of subpopulation-specific precursor cells FgfR2IIIb positive or, 
alternatively, the exposure of KGF stimulates the secretion of other growth and differentiation 
factors which in turn triggers now all thymic epithelial cells regardless of whether they express 
the KGF-specific receptor. Whether the FgfR2IIIb positive thymic epithelial identify a specific 
cell type with distinct functional characteristics is not yet known. Experiments have therefore 
been initiated that seek to determine whether KGF displays in addition to its potent mitogenic 
effect also a potential for thymic epithelial cell differentiation. It is, however, conceivable 
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that FgfR2IIIb positive cells can undergo an asymmetric division whereby the daughter 
cells are phenotypically and functionally divergent in comparison to the FgfR2IIIb positive 
precursor cells. In this context, it was also noted that the thymic FgfR2IIIb expression density 
and pattern as analyzed by immunohistology did not change following KGF stimulation, a 
finding confirmed by quantitative PCR (data not shown). Finally, other stromal cell types such 
as fibroblasts, dendritic cells, and macrophages do not express FgfR2IIIb and their expansion 
following the exposure to KGF is therefore the consequence of successful signaling in thymic 
epithelial cells.
Experiments were carried out to elucidate the molecular mechanisms by which KGF enhances 
thymic epithelial cell proliferation and thymocyte development. Little is presently known 
regarding target genes of KGF signaling, be it in the normal physiological steady-state 
condition of organ maintenance or be it following cell injury after specific insults (168-170). 
Coinciding with the relatively late discovery of FgfR2IIIb, a precise knowledge of the signaling 
pathways engaged by KGF ligand binding to is receptor has not sufficiently been detailed yet. 
To identify KGF target genes in adult thymic epithelial cells, naive mice were treated with either 
KGF (15 mg/kg/day) or HBSS. Epithelial cells were then isolated 24 hours after injection and 
subjected to cDNA generation and quantitative RT-PCR analysis. In a first step, transcripts for 
IL-7, the bone morphogenic proteins (BMP) 2 and 4 and particular members of the Wnt family 
were quantified since these factors have previously been identified to play a role in epithelial 
cell development and early thymopoiesis. IL-7 acts as an important survival factor for early 
thymopoiesis and its specific receptor, IL-7R is expressed on TNI cells. While speculations have 
been made that functional IL-7R is also expressed on thymic epithelial cells, data supporting 
this claim are so far not been published. The bone morphogenic proteins are part of the TGF-β 
superfamily of multifunctional factors and participate in developmental events as diverse as 
patterning of the early embryonic mesoderm, epithelial-mesenchymal interactions, apoptosis 
and inhibition of early thymocyte development (171-174) and review in (175). BMP2 and BMP4 
may therefore act directly on several cell types present in the thymus including the lymphoid 
compartment. Wnt molecules constitute a family of 18 different glycoproteins, which control 
functions such as cell fate specification, proliferation, migration, polarity and cell death. An 
involvement of the Wnt signaling pathway in thymus organogenesis has been suggested by 
experiments demonstrating that thymic epithelial cells can receive Wnt-mediated signals and 
that the transcription factor FoxN1 is upregulated in response to Wnt4 and Wnt5b but not Wnt1 
(176). Moreover, blocking Wnt activity by the provision of soluble Wnt receptors, solFz result 
also in a partial maturational block of the progression of TN to DP thymocytes. Since lymphoid 
cells normally express on their cell surface several of the Wnt-specific receptors, changes in 
Wnt availability can affect their growth and differentiation in either an autocrine as a paracrine 
fashion (152, 177). The treatment of adult mice with KGF resulted in a robust upregulation of 
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IL-7 transcripts in thymic epithelial cells, in a modest increase in mRNA for Wnt4, Wnt5b and 
Wnt10b, and in a significant stimulation of BMP2 and BMP4 transcription. Biological effects 
of these molecules on thymic epithelial cell proliferation (and possibly differentiation) are 
plausible but will have to be tested formally. Not knowing the precise molecular mechanisms 
by which KGF stimulates changes in thymic lymphoid and stromal cellularity, changes in the 
effector molecules operational in thymocyte-epithelial cell crosstalk are a likely explanation for 
this observed phenomenon. To detail the global transcriptional changes brought about by KGF 
signaling to thymic epithelial cells, experiments are presently under way to analyze, by use 
of gene chip, the transcripts of in vivo stimulated and unstimulated primary thymic epithelial 
cells. These experiments are also designed to address the possibility that the thymic epithelial 
cell precursors with an MTS24+ phenotype may respond in a different fashion to KGF than the 
population of phenotypically mature cortical or medullary thymic epithelial cells. 
In a separate set of experiments, thymic organ cultures depleted of lymphoid cells were also 
analyzed for changes in gene transcription in response to KGF. To this end the lobes harvested 
at E15.5 of gestation were first exposed for 6 days to 2dGuo prior to KGF stimulation. Although 
this treatment does not arrest thymic tissue maturation at the chronological age of isolation, 
epithelial cells did not acquire a mature phenotype at the time KGF was added to cultures. 
Several differences have been noted when comparing changes in transcripts stimulated by 
KGF in fetal thymic epithelial cells with those derived from adult thymic epithelial cells. An 
upregulation of IL-7 transcripts was not detected after KGF stimulation of embryonic thymic 
stromal cells, while mRNA-specific for IL-7R increased in these cells by approximately 7-
fold. Although not yet independently verified, these results would certainly argue for the 
expression of IL-7 receptor on thymic stromal cells. The pattern of KGF-mediated upregulation 
of Wnt molecules was considerably different when compared with the corresponding changes 
observed in adult thymic epithelial cells. An explanation for this discrepancy might be 
reflective of the general differences observed when comparing the gene expression profiles of 
specific molecules between fetal and adult cells of a given tissue. Interestingly, transcripts for 
FoxN1 were severely decreased as a consequence of KGF signaling. This result is unexpected 
as the lack of FoxN1 causes an athymic phenotype known as “nude” but KGF-mediated 
signaling via FgfR2IIIb has been viewed as critical for thymic epithelial cell development of 
the organ primordium (60). While it appears likely that FoxN1 transcription is not inhibited 
in the presence of physiological KGF concentrations, three additional observations suggest 
that pharmacological doses of KGF decrease FoxN1 transcripts. First, low FoxN1 messages 
parallel the lack of an upregulation of Wnt4 and 5b in response to KGF. These specific Wnt 
family members have previously been demonstrated to enhance the transcription of FoxN1 
(176). Second, preliminary experiments, in collaboration with Y. Takahama (Division of 
Experimental Immunology, Institute for Genome Research, The University of Tokushima, 
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Japan), have analyzed the repopulation of thymic lobes by early precursor cells revealed a 
decreased capacity for the homing of immature thymocytes to microenvironment previously 
exposed to KGF. Third, the absolute number of early thymic precursors (ETP (36)) has been 
found to be decreased in adult mice exposed 9 days earlier with pharmacological doses of KGF 
(unpublished data). 
The pathways by which KGF signaling is transduced to stimulate changes in gene transcription 
have not yet been characterized. In analogy to the signaling pathways activated by other FGF 
receptors, experiments were designed to determine whether binding of KGF to its specific 
receptor also activates signaling through NFκB, ras, or p53. To this end, thymic fetal lobes 
depleted of lymphoid cells by 2dGuo treatment were exposed to KGF in the presence or 
absence of separate, specific inhibitors. None of the KGF-triggered transcriptional changes 
appeared to be controlled exclusively by only one of the second messengers. For example, 
BMP2, but not BMP4, transcription was abrogated when ras activity was blocked but neither 
Wnt10b nor IL-7R expressions were affected in the presence of NFκB, ras, or p53 inhibitors. 
In contrast, inhibition of FoxN1 transcription by KGF was lost when ras and p53 were 
inactivated. Finally, it also remains to be defined how KGF exerts its cytoprotective effect 
on thymic epithelial cells after injury by radiation or GVHD. Observations in experimental 
models focusing on epithelium of the respiratory or alimentary tract have recently begun to 
light on the mechanism of protection. For example, the protection exerted by KGF on lung 
and intestinal epithelial cells from radiation-induced damage is paralleled by reduction in 
apoptosis and sustained proliferation (178-180). Furthermore, experimental evidence suggests 
that stabilization of actin filaments (F-actin), important cytoskeletal structure that allow 
formation of stable construction in the cells and are also fundamental for cell movement, 
via a PKC-dependent pathway is associated with resistance to radiation (179). However, 
it remains to be established whether this association is coincidental or causal. Finally, KGF 
signaling may also cross-talk to establish pathways to enhance cell survival and resistance to 
cell damage. For example, irradiated and HSC-transplanted mice treated with a combination 
of p53 inhibitor and KGF revealed a robust decrease in tissue damage of pulmonary, intestinal 
and skin epithelium in an experimental model of acute GVHD when compared to recipients 
treated only with one of these pharmacological blockers. In addition, histological analyses of 
thymic sections of mice irradiated and HSC-transplanted treated with p53 inhibitor and KGF 
revealed a normal cellularity and tissue architectural organization, while animals treated with 
only one of these molecules demonstrated limited structural deficiencies (data produced in 
collaboration with Bruce Blazar, University of Minnesota Cancer Centre, Minneapolis).
The in vivo treatment of adult mice with KGF results in a proportional increase of all thymocyte 
subpopulations by 2- to 3-fold. Phenotypic analyses at the different developmental stages 
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and the use of the Vβ repertoire of positively selected, mature SP thymocytes did not reveal 
differences when compared to control mice. Thus, KGF treatment stimulates an elevated 
level of thymopoiesis without affecting thymocyte maturation or selection. Moreover, this 
KGF-effect is long-lasting as the increase in thymic size and cellularity was evident for at 
least 3 months. Differences in the KGF responsiveness as a function of age were, however, not 
observed. In preliminary experiments, mice older then 12 months were treated with KGF and 
responded with an increase in thymic cellularity similar to young animals. The KGF-effect is 
not restricted by the senescence of thymic tissue albeit age-dependent changes are somewhat 
limited in mice when compared to humans. 
The initial effect of KGF on thymocyte production in adult mice appears to affect preferentially 
cells with a TN phenotype. Kinetic studies assessing changes in thymocyte subpopulations 
demonstrated a burst of TNI and TNII proliferation early after the provision of KGF. Since 
this effect is paralleled by an upregulated expression of IL-7, it is likely that the increased 
survival of IL-7R+ cells is effected by this cytokine. Prior to stimulation of TN cells, KGF has 
creates a larger stromal compartment able to accommodate more developing thymocytes. 
While this interpretation of the data consist in an attractive model, several issues related to the 
observed biological functions of KGF remain to be addressed. For example, it is not known yet 
whether the increased transcripts expression of BMP2 and BMP4 specific affect the TN -> DP 
-> transition in treated adult mice. Similarly, changes in Wnt expression have the theoretical 
potential to either enhance or block early thymocyte development. It will be the task of further 
experiments to dissect the molecular mechanisms leading to a sustained enhancement of 
thymopoiesis following the short-term exposure to KGF. 
Comparing the effect of KGF in adult thymic tissue with the changes in fetal thymic organ 
cultures, revealed several differences. For example, the accumulation of TNI thymocytes and 
the concomitant loss of cells with a more mature phenotype were specific for fetal tissue. Since 
little to no IL-7 is being produced in thymic organ cultures in response to KGF, a lack in the 
survival of IL-7R bearing immature thymocytes may serve as an explanation for these results. 
Experiments supplementing fetal thymic organ cultures with exogenous IL-7 are presently 
under way to test this contention directly. Interestingly, the exposure of fetal lobes to KGF 
was limited to 48 hours but the disruption of thymocyte development was still apparent 20 
days later. Moreover, the changes observed are particularly marked by the loss of DP cells. 
Since there is not a complete lack of TNIV cells, a block in the differentiation of TN cells to 
DP cells seems to be a likely explanation.  This specific developmental transition is under the 
control of several thymocyte-intrinsic signals including the productive rearrangement of the 
T cell antigen receptor β-chain and the successful signaling via the pre-T cell antigen receptor. 
In contrast, little is presently known regarding the requirements provided by the thymic 
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microenvironment to achieve this maturational progression. Although BMP2 and BMP4 have 
been previously demonstrated to exert a block in the TN -> DP -> transition, their functional 
involvement in the long-term fetal thymic organ culture experiments described here is far 
from clear, least for the reason that gene profiling has not been performed on fetal tissue other 
than 24 hours after KGF treatment.
Experiments to detail the export of thymocytes in adult mice revealed that mice treated with 
KGF show an increased export of early thymic emigrants, both CD4+ and CD8+ to the spleen 
within 16 hours, but only at the time were the thymus has reached the stable steady state after 
treatment. The discrepancies within the migration of early thymic emigrants in the spleen and 
in the lymph nodes, where no significant increased in this population was detected, could 
be explained by the homing pattern capacity that could differs between spleen and lymph 
nodes.
Despite the systemic presence of acute GVHD, KGF preserved normal thymic development as 
revealed by typical cellularity, frequency and cellular proliferation of the different immature 
and mature thymocyte subsets. The structure of the thymic microenvironment following 
exposure to KGF was almost normal, as assessed by the regular cellular compositions of 
several thymic epithelial cell compartments. The hypothesis that this effect was a direct 
consequence of KGF on thymic epithelial cells as thymic epithelial cells but not thymocytes 
or other stromal elements specifically express the KGF receptor was confirmed by analysis 
of the peripheral compartment, where no changes between the allogeneically transplanted 
and KGF treated group and the allogeneically transplanted and saline treated group were 
detected. Treatment with KGF also reduced CD80 expression, possibly rendering thymic 
epithelial cells less likely targets to allogeneic T cell recognition. Interestingly, the absolute cell 
number of mature donor T cells in B6 -> B6D2F1 recipients treated with KGF was, however, 
significantly increased. Finally, KGF treatment was shown to affect the transcriptional activity 
of several genes described to play an important role in thymic epithelial cell function when 
measured under these conditions. The conclusion was therefore that thymic epithelial cells are 
targets of GVHD and the hypothesis that prevention or reversal of thymic epithelial cell injury 
by KGF has a beneficial effect on developing thymocytes by allowing a normal cross-talk to 
occur between thymic epithelial cells and thymocytes was confirmed.  Recent investigations 
concerning issues of the mesenchymal-epithelial cell interactions, the morphogenesis of 
epithelium and the mechanisms operating in cutaneous wound repair have identified KGF 
as a highly specific and potent mitogen (43, 59, 63, 64). Thymic epithelial cells have been 
reported to bear cell surface markers common with epithelia of other organs, in particular the 
epidermal keratinocytes in the skin (181). Despite these phenotypic similarities it is important 
to recognize that the capacity to efficiently support development and selection of T cells is a 
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unique feature of thymic epithelial cells (182). The observations that FgfR2IIIb is expressed 
only on thymic epithelial cell cells and not on other stroma cells or thymocytes strongly imply 
that treatment with KGF affected thymic epithelial cells and the effects observed in this GVHD 
model were due to changes in thymic epithelia. Although it is not possible to completely 
rule out an indirect contribution of KGF acting via modulation of peripheral GVHD, the 
central effect of KGF on thymopoiesis is much more relevant for the above and the following 
reasons: clinical assessment of GVHD comparing the HBSS and KGF treatment groups did 
not reveal significant changes in this model (data not shown); and a role for glucocorticoids 
as effectors of the observed thymic changes (i.e. loss of DP cells and hypocellularity) has been 
ruled out in this model (129). Cytoprotection constitutes a promising approach to ameliorate 
epithelial injury inflicted by GVHD. KGF has recently been recognized as an agent for 
epithelial cell repair in different GVHD target organs. Administered to mice before extensive 
conditioning and bone marrow transplantation, KGF ameliorated both survival and GVHD 
related pathologies in liver, lung and skin but not in spleen, colon and ileum (183). Similarly, 
in these experiments, splenic GVHD was not alleviated. In other experimental systems, an 
increased survival of transplant recipients was also observed when KGF was administered 
prior to total body irradiation, either alone or in combination with chemotherapy (55, 184). 
Here, KGF treatment protected the gastrointestinal epithelium from radiation- and immune-
mediated injury, reflecting variations in the clinical outcome depending on the choice of the 
experimental model used and the duration of KGF administered. Despite these differences, 
the central biological response to pharmacological doses of KGF was due to a potent trophic 
effect that may very well be specific for individual tissues. For example, the KGF effect on 
intestinal epithelium (185) included the survival of crypt stem cells (54), improved DNA repair 
(186) and an enhanced thickness of the entire mucosa (55) with an increased formation of 
goblet cells (187) and their secretory products (188, 189). Conversely, the decreased pulmonary 
damage observed after KGF treatment was secondary to enhanced epithelialization and the 
attenuation of immune-mediated injury (190). Thus, the pharmacological effects of KGF 
treatment are documented for tissues where KGF receptor expression has been convincingly 
demonstrated, e.g. intestinal epithelium, hepatocytes, skin keratinocytes, and alveolar type II 
cells (185, 191, 192). 
KGF protects thymic epithelial cells from cell injury not preventing the activation of donor 
cytotoxic T cells. Indeed, the relative number of activated donor T cells is increased in 
transplant recipients treated with KGF when compared to the control population. Although 
these cells represented only a very small fraction of all thymic T cells in the former treated 
group, these donor derived mature T cells are first detected in the thymus as early as day 9 
and are not activated, the activation marker CD69+ on donor T cells in the thymus is acquired 
only at day 11 post cell transfer. A decrease in epithelial cell allogeneicity as a consequence 
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of KGF exposure is a plausible explanation for the observed protection of the epithelial cell 
compartment. The diminished cell surface expression of the costimulatory molecule CD80 on 
thymic epithelial cells in mice treated with KGF when compared to mice with unmitigated 
thymic GVHD. The engagement of this costimulatory molecule is critical for a T cell response to 
both nominal and alloantigens (164). An upregulation of CD80 expression on thymic epithelial 
cells is a typical feature of thymic GVHD in untreated mice. It therefore seams likely that 
initially allogeneic T cells are activated in situ by thymic epithelial cells, not only expressing 
MHC molecules, but that are equally competent to provide the necessary costimulatory signal 
for their allorecognition by donor T cells. Reduction of CD80 expression as a consequence 
of KGF treatment may therefore render these cells less efficient stimulators and targets of 
allorecognition. Finally, the expression of MHC Class II on thymic stroma cells (as measured 
by immunohistology) did not revealed differences between allogeneically transplanted mice 
treated with KGF and those injected only with HBSS. The incomplete activation of donor-
derived T cells, as an indirect function of KGF, is furthermore mirrored by a decrease in the 
expression of transcript for granzyme B and Mip-1, usually only minimally detected in mature 
intrathymic T cells. Mip-1 constitutes a typical hallmark for activated T cells. Independent 
of these changes among the infiltrating T cells, the minor medullary epithelial cells (UEA-1+) 
disappear by day 13 after induction of GVHD independently of the mice received KGF or 
HBSS. The molecular mechanism by which these epithelial cells are destroyed is presently not 
known.
The loss of the UEA-1+ minor medullary epithelial cells in the course of GVHD seams to 
correlates with the downregulation of Aire, a transcription factor implied in the promiscuous 
gene expression in the thymus. A mutation in this transcription factor leads to the development 
of the autoimmune polyendocrinopathy syndrome (APS-1, a.k.a. APECED) (160, 161, 193-
196). Whether mice with acute GVHD rescued by KGF treatment will now develop such 
an autoimmune disorder reminiscent of APS-1 is not yet known. However, the serum of 
allogeneically transplanted mice that had been treated with KGF contained anti-nuclear auto-
antibodies, a characteristic serological feature of the chronic GVHD (92-97). Whether a state of 
chronic GVHD represent the price to be paid by KGF treated mice for escaping death by acute 
GVHD remains to be established.
Although the molecular mechanisms of KGF-mediated protection remain to be defined, the 
beneficial effects of KGF on thymic epithelial cells may be affected by different mechanisms. For 
example, KGF promotes the homeostasis of thymic epithelial cell proliferation, which in turn 
support regular thymopoiesis. KGF may also expedite the process of epithelial cell recovery 
following direct damage by cellular and humoral effector mechanisms of GVHD-mediated 
inflammation. In this context, it has recently been shown that KGF mediates a suppressive effect 
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on inflammation-induced gene expression as it prevents the interferon-stimulated trafficking 
of STAT1 from the cytosol to the nucleus (197). Furthermore, administration of KGF to animals 
prior to their conditioning by radio- chemotherapy had a long lasting beneficial effect on 
thymic function (183), underscoring a cytoprotective mechanism for this factor. Enhancement 
of mechanism of protection of thymic epithelial cell function and the modulation of thymic 
epithelial cell allogeneicity are not mutually exclusive. 
With its defined role as a cytoprotective agent for epithelial cells, enhanced production of 
endogenous KGF may thus constitute an adjunct strategy for GVHD treatment following 
allogeneic BMT. For example, expression of KGF is subject to negative regulation such as 
glucocorticoids, a standard component of GVHD therapy that decreases KGF mRNA in a 
time- and concentration-dependent manner (198). In consequence, it may be of clinical benefit 
to administer exogenous KGF in a pharmacological dose prior to conditioning and in the 
presence of thymic GVHD.
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